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ABSTRACT 
 
Sarah Maria Taylor:  VEGF REGULATES CENTROSOME DUPLICATION 
AND DIVISION ORIENTATION IN ENDOTHELIAL CELLS OF 
DEVELOPING BLOOD VESSELS 
(Under the direction of Victoria L Bautch) 
 
Blood vessel formation is critical for vertebrate development and is required 
for the progression of many diseases, including cancer.  Thus, understanding 
how blood vessels form and function is a necessary prerequisite to treating and 
preventing human disease.  Vascular Endothelial Growth Factor-A (VEGF) 
activates signaling cascades in endothelial cells to promote survival, migration 
and proliferation; and elevated VEGF signaling yields overgrown, dysfunctional 
vessels.  Tumor vessels experience high VEGF signaling and are abnormal in 
many ways.  Of interest, tumor vessels have excess centrosomes and display 
aneuploidy; and they are tortuous and over-grown.  I hypothesized that these 
abnormalities result from elevated VEGF signaling.  I used developmental 
models of elevated VEGF signaling to test my hypothesis.  I showed that VEGF 
gain-of-function flt-1-/- embryonic stem (ES) cell-derived vessels and in vivo yolk 
sac vessels display centrosome over-duplication and aneuploidy.  Moreover, 
VEGF signals through MEK/ERK and AKT to cyclin E/Cdk2 to promote 
centrosome over-duplication.  Interestingly, cells with excess centrosomes are 
enriched at the leading edge of in vitro scratch wounds, indicating that 
endothelial cells with excess centrosomes have a migratory advantage.  I also 
wondered if elevated VEGF signaling affects endothelial cell division orientation 
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to disrupt proper vascular morphogenesis.  In collaboration with Dr. Gefei Zeng, I 
showed that endothelial cell divisions are normally oriented to increase the long 
axis of developing vessels in ES cell-derived vessels and in vivo in neonatal 
retinal vessels.  Furthermore, flt-1-/- endothelial cell divisions are randomly 
oriented compared to wildtype divisions.  Randomized division orientations lead 
to dysmorphogenesis in other tissue types and it is possible that randomized 
endothelial cell divisions contribute to vascular dysmorphogenesis.  My data 
describe new roles for VEGF signaling during developmental blood vessel 
formation and suggest novel mechanisms as to how pathological vessels, such 
as tumor vessels, become abnormal. 
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CHAPTER I 
GENERAL INTRODUCTION 
 
Proper blood vessel formation and function is critical for the survival of 
vertebrate organisms, and aberrant blood vessel function can result in tissue 
death.  Indeed, the top three causes of death in the United States of America 
(heart disease, cancer and stroke) either result from dysfunctional existing blood 
vessels (heart disease and stroke) or depend on new blood vessel formation for 
disease progression (cancer).1  Thus, understanding how blood vessels form and 
function is a necessary prerequisite to treating and preventing several debilitating 
human diseases.  The data described herein focus on understanding the 
morphological and cellular processes that occur during normal blood vessel 
formation, as well as how these processes are perturbed when developing blood 
vessels are exposed to high Vascular Endothelial Growth Factor-A (VEGF) 
signaling.  Because VEGF is a critical regulator of blood vessel formation during 
embryonic development and pathogenesis, these data are a significant 
contribution toward understanding normal and pathological vascular biology. 
 
A.  Mechanisms of blood vessel formation 
Early blood vessel formation occurs via two sequential processes:  
vasculogenesis and angiogenesis.  Vasculogenesis is the process whereby 
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mesoderm-derived angioblasts differentiate into endothelial cells and coalesce to 
form primitive blood vessels.  Angiogenesis is the process by which existing 
blood vessels branch and form new vessel connections to yield a branched 
vascular plexus.  During angiogenesis, vessels become lumenized and the onset 
of blood flow initiates vascular remodeling.2  During remodeling, the existing 
plexus reorganizes so that large vessels connect to progressively smaller vessels 
to ultimately reach every cell in the body.2  My research addresses regulation of 
angiogenesis using developmental models of blood vessel formation. 
Blood vessel formation occurs in response to growth-promoting signaling 
proteins that are secreted by surrounding tissues.  Such signaling proteins 
include, but are not limited to, basic Fibroblast Growth Factor-2 (bFGF), Bone 
Morphogenetic Protein (BMP), Transforming Growth Factor beta (TGF-β) and, 
perhaps the most critical vascular signaling molecule, VEGF.  
 
B.  Vascular Endothelial Growth Factor-A 
The requirement for Vascular Endothelial Growth Factor-A (VEGF) signaling 
during blood vessel formation is evident by the fact that deletion of VEGF or 
VEGF receptors is lethal due to severe embryonic vascular defects.3-8  
Endothelial cells express numerous VEGF receptors, including Flk-1 (VEGFR-2) 
and Flt-1 (VEGFR-1).  Flk-1 contains an extracellular VEGF-binding domain, a 
transmembrane domain and a tyrosine kinase domain.  It binds VEGF as a 
homodimer or as a Flk-1/Neuropilin-1 heterodimer.3  VEGF/Flk-1 binding initiates 
protein signaling cascades in endothelial cells to promote endothelial survival 
and vascular permeability (AKT signaling), migration (p38MAPK signaling) and 
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proliferation (MEK/ERK signaling).3  Thus, VEGF signaling through Flk-1 
promotes angiogenesis.  Consistent with this model, Vegfa deletion or 
heterozygosity, or flk-1 deletion result in avascular embryos and early embryonic 
death.3-8 
The VEGF receptor Flt-1 is expressed by endothelial cells and is present as 
two differentially spliced isoforms, membrane-bound Flt-1 (mFlt-1) and 
soluble/secreted Flt-1 (sFlt-1).  mFlt-1 is similar to Flk-1 with regard to protein 
structure.  However, during development, VEGF binding to mFlt-1 does not elicit 
a downstream signaling response that is required for blood vessel formation.  
Likewise, VEGF binding to sFlt-1 does not elicit a downstream signaling 
response in endothelial cells, because sFlt-1 contains only the extracellular Flt-1 
domain and is secreted into the extracellular matrix (ECM).9-14  Our lab and 
others proposed a model in which Flt-1 acts as a VEGF sink to inhibit VEGF/Flk-
1 binding.  In this scenario, endothelial cells can self-regulate the level of Flk-1 
activation by VEGF.12,14   Consistent with Flt-1’s function as a VEGF sink, 
deletion of flt-1 is a VEGF gain-of-function perturbation, and results in dramatic 
vascular overgrowth and embryonic death, due to increased endothelial 
proliferation and decreased vessel branching.9-14   Work from our lab showed that 
restoration of sFlt-1 function in flt-1-/- vessels rescues vascular morphology more 
efficiently than mFlt-1 restoration, suggesting that Flt-1-mediated sequestration of 
VEGF protein in the ECM may be more effective than sequestration at the 
endothelial cell membrane.15 
VEGF-A is primarily expressed as three differentially-spliced isoforms:  
VEGF120, VEGF164 and VEGF188, with superscript designations referring to the 
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number of amino acids present in the mouse protein isoforms.  The isoforms 
differ in the number of heparin sulfate proteoglycan-binding domains present, 
and thus the ability to bind heparin in the ECM.  VEGF120 does not contain 
heparin-binding domains and is thought to diffuse the farthest distance from 
VEGF-secreting cells.  VEGF188 contains two heparin-binding domains and is 
thought to have very limited diffusion capability because heparin binding “tethers” 
VEGF188 near VEGF-secreting cells.  VEGF164 contains one heparin-binding 
domain and is thought to diffuse at an intermediate distance relative to VEGF120 
and VEGF188.16,17  Thus, simultaneous expression of all three VEGF isoforms is 
thought to contribute to the establishment of a VEGF gradient, which endothelial 
cells sense (based on localized Flk-1 activation) and migrate toward. 
Interestingly, the three VEGF isoforms are rarely expressed at equal levels.18  
In fact, genetically manipulated mice that express only one of the three isoforms 
are viable, save for VEGF120/120-expressing mice, which die soon after birth from 
cardiac abnormalities.  Vascular phenotypes in single VEGF isoform-expressing 
mice are apparent in the mouse neonatal retina.  VEGF120/120 retinal vessels are 
thick and less branched compared to wildtype vessels.  This phenotype is 
thought to result from the inability of endothelial cells to properly sense a VEGF 
gradient due to high VEGF120 diffusion.17  Conversely, VEGF188/188 retinal vessels 
are thin and highly branched compared to wildtype vessels.  This phenotype is 
thought to result from numerous small VEGF gradients that are established due 
to VEGF188 heparin “tethering”.17  VEGF165/165 retinal vessels are similar to 
wildtype vessels due to intermediate diffusion of VEGF165 protein.17  The 
phenotypes of single isoform-expressing mice are consistent with isoform 
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expression patterns in wildtype animals.  For example, in lungs, where VEGF188 
is the dominantly expressed isoform, vessels are thin and highly branched.18 
In addition to the VEGF-A/(flk-1/flt-1) mode of endothelial cell signaling, there 
are a number of other VEGF ligands and receptors which regulate a variety of 
cellular processes.  For example, VEGF-B and PlGF bind Flt-1 in macrophages 
to affect migration.  VEGF-C and -D bind Flk-1 and Flt-4 to regulate 
lymphangiogenesis.3,19  A number of parapox virus open reading frames share 
sequence homology with traditional VEGFs and these are grouped together as 
VEGF-E.  VEGF-E is not present in vertebrates, but can bind Flk-1.  NRP-1 and -
2 can act as co-receptors for VEGF-A, -C and -D.  Each VEGF/VEGFR/NRP 
combination is important for a specific regulatory function in a specific cell 
type.3,19  I am primarily interested in investigating VEGF-A/(Flk-1/Flt-1) 
interactions because these ligands/receptors seems to be the most important for 
regulating blood vessel formation. 
In addition to critical roles in normal angiogenesis, altered VEGF signaling is 
also causal for a number of pathological processes.  Cancer is perhaps the most 
well-characterized disease that requires VEGF signaling.  Tumors can only grow 
a few millimeters in size until they must recruit blood vessels to obtain oxygen 
and nutrients.  To recruit new vessels, tumor cells secrete very high levels of 
VEGF.  High VEGF signaling causes nearby established blood vessels to 
become angiogenic and migrate toward the VEGF signal (the tumor cells).19,20  
Once a tumor is vascularized, it can grow and spread to other organs via the 
blood vessels, a process termed metastasis. 
6 
 
For many years, it was assumed that tumor endothelial cells were genetically 
the same as normal endothelial cells.  This assumption lead to the development 
of a number of anti-tumor therapies aimed at inhibiting tumor angiogenesis.  The 
majority of anti-angiogenesis therapies used to date are anti-VEGF therapies that 
are surprisingly ineffective at inhibiting tumor angiogenesis in long-term clinical 
trials.21  Recently, a number of tumor vessel abnormalities were described.  It is 
possible that the ineffectiveness of anti-VEGF treatments is due to these tumor 
vessel irregularities. 
Tumor vessels are abnormal in a number of ways.  They are abnormal 
morphologically, in that there is little to no hierarchical organization (large vessels 
vs. capillaries) and the vessels are abnormally dilated.21-23  At the cellular level, 
tumor endothelial cells display increased permeability (leakiness), have excess 
centrosomes, and exhibit aneuploidy compared to normal endothelial cells.21-25  
Elevated VEGF signaling promotes vessel permeability and abnormal vessel 
morphology, indicating that elevated VEGF signaling in tumors may lead to the 
abnormalities observed in tumor vessels.  My work describes roles for VEGF 
signaling in regulating two critical cellular processes:  centrosome duplication and 
cell division orientation.  Elevated VEGF signaling disrupts both processes, 
resulting in vascular abnormalities.  These novel discoveries provide insight into 
how elevated VEGF signaling, such as that found in tumors, could lead to 
vascular irregularities during development and disease. 
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C.  Overview of centrosome duplication 
In 1888, Theodor Boveri first described the centrosome as the “special organ 
of cell division”.26  Using a light microscope, he was able to determine that the 
centrosomes bundled microtubules to regulate chromosome allocation during 
mitosis.  Later, Boveri used sea urchin embryos to demonstrate that embryos 
with excess centrosomes displayed aneuploidy and abnormal development.  He 
also speculated that aneuploidy would contribute to cancer.26  Although Boveri 
observed how important proper centrosome number is to cellular fidelity over 100 
years ago, we are only recently beginning to understand how centrosome 
number is regulated. 
Centrosomes are cellular organelles that act as the microtubule organizing 
center (MTOC) during interphase and mitosis.  Centrosomes are composed of 
two orthogonal barrel-shaped microtubular structures called centrioles, which are 
surrounded by a cloud of microtubule-nucleating proteins, termed pericentriolar 
material (PCM).  Just prior to mitosis, two closely associated centrosomes are 
present in the cell.  Upon mitotic entry, the centrosomes separate and migrate to 
opposite ends of the cell to form the spindle poles.  Following mitosis and 
cytokinesis, each daughter cell contains one centrosome.  The centrosome 
duplicates during S phase of the cell cycle to ensure that only two centrosomes 
are present during the subsequent mitosis.27 
Centrosome duplication, like cell division, is regulated by cell cycle cues.  
Genetic knockout of the tumor suppressor gene p53 results in centrosome over-
duplication in cultured mouse fibroblasts, and p53 loss of function is associated 
with centrosome over-duplication in vivo in tumor cells.28  During the G1/S cell 
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cycle transition and throughout S phase, p53 is activated in response to DNA 
damage.  Activated p53 blocks cell cycle progression via transcriptional 
regulation of cell cycle regulating proteins, thus allowing DNA repair machinery 
sufficient time to repair damaged DNA.28  During the G1/S cell cycle transition, 
activated p53 promotes transcription of p21.  p21 inhibits the cell cycle promoting 
complex cyclin E/Cdk2; thus, p53 is an inhibitor of cyclin E/Cdk2.28  Interestingly, 
cyclin E overexpression, like p53 loss-of-function, leads to centrosome over-
duplication in mouse fibroblasts, and cyclin E is often overexpressed in tumors 
that display centrosome over-duplication.29-33 
To promote centrosome duplication, cyclin E/Cdk2 phosphorylates a protein 
called Nucleophosmin-1 (NPM).34  Prior to cyclin E/Cdk2-mediated NPM 
phosphorylation, NPM is located at the centrosome, where it is thought to 
stearically inhibit centrosome duplication.  Upon phosphorylation, NPM leaves 
the centrosome and translocates to the nucleus, where it is involved in ribosome 
biogenesis.  Inhibition of cyclin E/Cdk2-mediated NPM phosphorylation inhibits 
centrosome duplication, and genetic loss of NPM leads to centrosome over-
duplication.34 
In endothelial cells, integrin activity seems to be important for centrosome 
duplication.  Focal Adhesion Kinase (FAK) deletion or expression of a Serine-732 
non-phosphorylatable version of FAK leads to centrosome over-duplication in 
cultured endothelial cells.35  A number of additional molecules play roles in 
centrosome duplication, including Separase and Polo-like Kinase 4; however, if 
and how these molecules regulate cyclin E/Cdk2 activity is unclear.36 
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Centrosome over-duplication is observed in many tumors and is typically 
accompanied by aneuploidy.37  Tumor blood vessels also display aneuploidy and 
have excess centrosomes.24,25  This suggests that the presence of excess 
centrosomes in tumor endothelial cells contributes to tumor blood vessel 
dysfunction.  Cells containing excess centrosomes can form aberrant spindles 
during mitosis, resulting in aneuploidy.37  Aneuploid cells are typically abnormal 
due to changes in gene expression levels.  Additional abnormalities associated 
with excess centrosomes have not been described.  Here, I show that VEGF 
signals through MEK/ERK and AKT to cyclin E/Cdk2 to promote endothelial 
centrosome duplication, and elevated VEGF signaling promotes centrosome 
over-duplication.  I also show that endothelial cells with excess centrosomes form 
aberrant mitotic spindles and display aneuploidy and abnormal migration.  These 
data are a significant contribution toward understanding how elevated VEGF 
signaling contributes to centrosome over-duplication and vascular dysfunction. 
 
D.  Overview of cell division orientation 
Regulated cell division orientation is important for proper morphogenesis in a 
number of developing tissues.  For example, elongation of the zebrafish body 
axis during gastrulation and extension of the avian primitive streak are dependent 
on regulated division orientation.38,39  Additionally, shaping of the neural tube in 
avian and mouse models is associated with oriented division.40  In these cases, 
oriented cell divisions increase the length of the axis in which they divide to 
establish tissue shape.  When division orientation is randomized, tissue 
morphology is abnormal.  In the mature mouse aorta and in vitro, endothelial cell 
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division orientation is established in response to blood flow, such that the 
cleavage plane forms perpendicular to the direction of flow;41 however, it is 
unclear if endothelial cell division orientation is regulated independent of flow by 
other signaling inputs. 
Cell division orientation is regulated by a number of mechanisms.  One 
signaling pathway that regulates division orientation is planar cell polarity (PCP) 
signaling.  PCP signaling was described early on in D. melanogaster as the 
signaling pathway responsible for polarizing wing hairs, such that all hairs are in 
the same location and face the same direction in each cell.42  PCP regulates 
symmetric divisions during zebrafish body elongation and asymmetric divisions in 
C. elegans, fly and mouse.42  In some cases, the PCP pathway is initiated 
following Frizzled (Frz) receptor activation by a Wnt ligand; however, Wnt ligand 
activity is not necessary.  Activated Frz interacts with Disheveled (Dsh) and 
Daam proteins at the cell membrane to initiate a protein signaling cascade that 
modulates Jun Kinase (JNK) and Rho Kinase (ROCK).42  JNK and ROCK are 
thought to regulate cytoskeletal activity to affect division orientation.42  Whether 
or not PCP signaling is important in regulating vascular morphogenesis is 
unknown. 
Thery, et al. (2005) performed very elegant in vitro experiments which 
demonstrated that extracellular matrix patterning can regulate cell division 
orientation.  Briefly, the group micro-patterned glass slides with varying patterns 
of the ECM protein Fibronectin and placed a single cell on each pattern to assess 
division orientation.  They showed that cell shape during interphase (as regulated 
by the Fibronectin pattern) directly regulates the orientation of cell division during 
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mitosis.43  There is no known role for the ECM in regulating endothelial cell 
division orientation, but it is conceivable that ECM modulation might affect 
endothelial cell division orientation.  In collaboration with Gefei Zeng, I showed 
that endothelial cell divisions are oriented to increase the length of developing 
blood vessels in the absence of blood flow.  Elevated VEGF signaling leads to 
randomized endothelial cell division orientation and vascular dysmorphogenesis. 
Furthermore, we showed that PCP signaling may be involved in regulating 
endothelial cell division orientation. 
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CHAPTER II 
 
ANGIOGENIC FACTORS REGULATE CENTROSOME DUPLICATION IN 
ENDOTHELIAL CELLS OF DEVELOPING BLOOD VESSELS 
 
 
The majority of the work described in this chapter was performed by me.  
Cdk2 activity assays were performed in collaboration with Jean Cook and 
Kathleen Nevis at UNC.  An undergraduate researcher, Hannah Park, who I 
mentored, assisted with western blotting.  Chromosome number analysis was 
performed by Karyologic, Inc.  Substantial intellectual input was provided by 
Steve Rogers and Greg Rogers at UNC and the University of Arizona, 
respectively. 
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A.  Introduction  
Blood vessels supply both normal and diseased tissues with the oxygen and 
nutrients necessary for growth and survival.  Thus, proper blood vessel formation 
and expansion is critical for normal development, and for the progression of 
diseases such as cancer.1,2  Blood vessel networks expand via angiogenesis, a 
process whereby vessels form by sprouting migration from pre-existing vessels.  
Angiogenic expansion requires regulated endothelial cell division.  Endothelial 
cell division in developing vessels, as in other cells, is a tightly regulated process 
ensuring that DNA goes through only one round of replication per cell cycle.  The 
centrosome that comprises the microtubule organizing center during interphase 
also replicates only once per cell cycle, to provide two centrosomes that facilitate 
mitotic spindle assembly during mitosis.3  Cell cycle regulation is well 
characterized in terms of timing, checkpoints, and regulation of DNA replication.  
However, regulation of centrosome duplication is less well understood in general, 
and even less is known about how this critical cellular process is regulated in 
endothelial cells.  Centrosome over-duplication is associated with elevated cyclin 
E/Cdk2 activity in other cell types; loss of p53, which can inhibit cyclin E 
accumulation, also promotes centrosome over-duplication.4  Tumor endothelial 
cells have excess centrosomes and are aneuploid, but the signaling pathways 
responsible for this phenotype are unknown.5,6  
Endothelial cell proliferation and migration are normally tightly regulated to 
form proper vessels, and angiogenic factors, such as Vascular Endothelial 
Growth Factor-A (VEGF), play a central role in these processes.7,8  Developing 
vessels express several VEGF receptors, including Flk-1 (VEGFR-2) and Flt-1 
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(VEGFR-1).  Genetic loss of VEGF pathway components leads to vessel 
perturbations and embryonic lethality, but the phenotypes differ.  Homozygous 
loss-of-function for flk-1 or heterozygosity for Vegfa results in dramatically 
reduced blood vessel formation, since VEGF binding to Flk-1 positively activates 
downstream signaling that promotes endothelial proliferation, migration and 
survival.9-13  In contrast, loss of flt-1 leads to vessel over-growth and 
dysmorphogenesis that results from both increased endothelial cell proliferation 
and decreased vessel branching.14-16  We and others have shown that Flt-1 
functions developmentally as a VEGF sink to negatively modulate VEGF-
mediated signaling through Flk-1, and the flt-1-/- mutation thus behaves like a 
gain-of-function perturbation in VEGF signaling.17-19  Tumor endothelial cells are 
exposed to elevated VEGF levels produced by tumor cells, and tumor vessels 
also express low levels of Flt-1 compared to normal vessels, suggesting that 
multiple inputs promote excess VEGF signaling in tumor endothelial cells.20,21  
We hypothesized that signaling of angiogenic factors such as VEGF regulates 
centrosome number in endothelial cells, and that elevated VEGF mis-regulates 
endothelial cell centrosome duplication.  Our hypothesis predicts that endothelial 
cells with aberrant centrosome numbers are not restricted to tumor vessels, but 
are found more generally in any environment with elevated endothelial VEGF 
signaling.  Here, we show that elevated VEGF or FGF signaling leads to excess 
centrosomes in endothelial cells. This mis-regulation utilizes both MEK/ERK and 
AKT signaling pathways downstream of VEGF-A to enhance cyclin E/Cdk2 
activity. Furthermore, endothelial cells with excess centrosomes survive and form 
aberrant spindles during cell division, and vessels exposed to high VEGF 
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signaling have elevated levels of endothelial cell aneuploidy. These are the first 
data to link regulation of endothelial cell centrosome duplication to upstream 
VEGF signaling, and they highlight a novel mechanism that is likely to contribute 
to the dysfunction of vessels exposed to elevated angiogenic factor signaling.  
 
B.  Materials and methods 
Cell lines, yolk sacs and VEGF manipulations 
Wildtype (WT) and flt-1-/- mouse embryonic stem (ES) cells were differentiated 
for eight days as described previously.22,23  For analysis of differentiated and 
dissociated ES cell cultures, WT and flt-1-/- ES cell lines expressing H2B-eGFP 
downstream of the PECAM-1 promoter/enhancer were used.24  Cultures were 
dissociated for 20 min in trypsin-EDTA (Gibco  25300, Carlsbad, CA, USA), 
strained to eliminate clumps (70 µm Nylon strainer, BD Biosciences 352350, San 
Jose, CA, USA), and plated on 0.1% gelatin-coated dishes for 18 hr prior to 
fixation.  Human umbilical vein endothelial cells (HUVEC, Lonza Group Ltd., 
cc2519, Basel, Switzerland) were maintained in Endothelial Growth Medium-2 
(EGM-2) as suggested by Lonza Group Ltd (cc-3162). 
For centrosome counting experiments, HUVEC were cultured in low growth 
factor (EGM-2) medium, high growth factor (EGM-2 + 200 ng/mL growth factor) 
medium, or high growth factor medium + inhibitor.  Supplemented growth factors 
included VEGF165 and FGF-2 (Peprotech 100-20 and 100-18B, Rocky Hill, NJ, 
USA).  Inhibitors included U0126 (MEK inhibitor), AKT inhibitor, SB 203580 (p38 
MAPK inhibitor), and Bisindolylmaleimide I (PKC inhibitor) (Calbiochem  662005, 
124005, 559398, and 203290, Gibbstown, NJ, USA) and were applied at 5 µM, 
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10 mM, 10 µM and 10 µM, respectively.  Medium was replaced daily for 4 or 10 
days, and cells were maintained at 30-70% confluency. 
For HUVEC division rate analysis, HUVEC were plated at 103 cells/dish and 
cultured overnight in normal medium.  The next day (Day 0), cells were treated 
with low VEGF or high VEGF for 4 days, with medium replaced daily.  Cell 
number was scored daily for 4 days.  For signaling pathway analysis, HUVEC 
were serum-starved for 12 hr in Endothelial Basal Medium-2 (Lonza Group Ltd., 
cc-3156) supplemented with 0.1% fetal bovine serum (Gibco, 35-010-CV), then 
treated with low VEGF, high VEGF or high VEGF + inhibitor for 5 min, 1 hr or 12 
hr. Prior to inhibitor treatments, cells were incubated in serum starvation media + 
inhibitor for 1 hr.   For apoptosis experiments, HUVEC were cultured in high 
VEGF for 4 days with or without the addition of 20 µM 4-hydroxy Nonenal (HNE, 
Cayman Chemical, 32100, Ann Arbor, MI, USA) for the final 24 hr of the 4 day 
treatment, to induce apoptosis as described previously.25 
For flt-1-/- embryonic yolk sac analysis, flt-1+/- mice were inter-crossed and 
embryos were harvested on E9.5.  WT and flt-1-/- littermate yolk sacs were used 
for analysis after embryos were genotyped as described previously.15  Animal 
experiments were approved by the IACUC Committee at the University of North 
Carolina. 
 
Immunofluorescence and microscopy 
Differentiated ES cell cultures, cells dissociated from differentiated ES cell 
cultures, or HUVEC were fixed in ice cold 50% methanol/50% acetone for 5 min, 
and stained as described previously.22,23  Yolk sacs were fixed and stained as 
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described previously.26  Primary antibodies were raised against human protein 
sequences unless otherwise indicated and included rabbit anti-γ-tubulin (1:1000, 
Sigma T3559, St. Louis, MO, USA), mouse anti-pericentrin (1:1000, Abcam 
28144, Cambridge, MA, USA), rabbit anti-nucleophosmin-1 (NPM) (1:500, Santa 
Cruz Biotechnology, sc-6013-R, Santa Cruz, CA, USA), rat anti-mouse PECAM-1 
(1:1000, BD Pharmingen, 553370), rabbit anti-active Caspase 3 (1:500, Abcam 
Cat. #ab2302), rabbit anti-Caspase 3 (1:500, Abcam 44976), and rabbit anti-α-
tubulin (1:500, Abcam 15246).  Cy3-conjugated anti-γ-tubulin antibody was used 
for yolk sac labeling (1:250, Sigma C7604).  Secondary antibodies were used at 
1:250 and include goat anti-rat, donkey anti-rabbit, donkey anti-goat or goat anti-
mouse Alexa 488 (Molecular Probes, A11006, A21206, A11055 and A11029, 
Carlsbad, CA, USA) and donkey anti-rabbit Alexa 594 (Molecular Probes, 
21207).  Cells were stained with the DNA dye DRAQ5 for 30 min at RT (1:1000, 
Biostatus Limited, DR50050, Leicestershire, UK).  Confocal images were 
acquired using a Zeiss LSM 5 Pascal microscope.  For flow cytometry analysis, 
HUVEC were treated with low or high VEGF for 4 days as described above, fixed 
and stained with propidium iodide, and fluorescence activated cell sorting (FACS) 
was performed as described.27 
 
Western Blots and Cdk2 Activity Assay 
Western blot analysis was performed as previously described, with slight 
modifications.28  Briefly, HUVEC lysates were collected using Mammalian Cell 
Lysis Buffer (Fermentas, K0301, Burlington, Ontario, Canada) per product 
instructions and proteins were separated on a 10% SDS-polyacrylamide gel and 
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transferred to a polyvinylidene fluoride membrane (GE Healthcare, RPN303F, 
Hillsborough, NC, USA).  Primary antibodies raised against human protein 
sequences were used and included rabbit anti-cyclin E (1:500, Santa Cruz 
Biotechnology, sc-481), goat anti-actin (1:500, Santa Cruz Biotechnology, sc-
1615), rabbit anti-phospho-NPM (Thr199) (1:1000, Abcam, ab59353), rabbit anti-
NPM (1:1000, Abcam, ab15440), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204) 
(1:1000, Cell Signaling Technology, 9101S, Danvers, MA, USA), mouse anti-
ERK 2 (1:1000, Santa Cruz Biotechnology, sc-154), rabbit anti-phospho-AKT 
(Ser473) (1:1000, Cell Signaling Technology, 4060S), and rabbit anti-AKT 
(1:1000, Cell Signaling Technology, 9272).  Signal was detected with HRP anti-
rabbit (GE Healthcare, NA934V), HRP anti-mouse (GE Healthcare, NA931V) or 
HRP anti-goat (Santa Cruz Biotechnology, sc2020), and imaged via enhanced 
chemiluminescence (GE Healthcare, RPN2132).  For the Cdk2 activity assay, 
HUVEC were serum-starved and treated with low or high VEGF for 12 hr as 
described above.  The Cdk2 activity assay was performed as described 
previously.27  Briefly, 12 hr lysates were subjected to immunoprecipitation with 
anti-Cdk2 (Santa Cruz Biotechnology, sc-163).  Immune-complex kinase 
reactions were carried out in 25 µl kinase buffer containing 5 µg Histone H1 
(Sigma, H4524), 1 µM ATP, and 5 µCi [γ-32P]ATP (Perkin Elmer, 
BLU002A250UC, Waltham, MA, USA) and incubated at 30°C for 30 min.  After 
the reaction was stopped, proteins were separated on a 10% SDS-
polyacrylamide gel, and gels were dried and autoradiographed. 
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 Lentivirus transfection 
Human cyclin E-targeted shRNA vectors were obtained from the Open 
Biosystems TRC1 shRNA pLKO1 vector library (Open Biosystems, Huntsville, 
AL, USA).  Targeted sequences were TRCN0000045298, TRCN0000045299, 
TRCN0000045300, TRCN0000045301 and TRCN0000045302.  Virus was 
produced in 293T cells and collected at 36-60 hr post-transfection at a minimum 
of 1x106 IU/mL.  Cells were transfected with lentivirus for 6 hr at 37ºC and then 
treated with low or high VEGF medium for 4 days as described above.  Virus 
lacking a target sequence (empty vector) was used as a control.  
 
Chromosome number analysis 
Wildtype and flt-1-/- ES cells were differentiated for 8 days, dissociated for 30-
45 min in 2 mg/ml collagenase (Worthington 46S9287), and endothelial cells 
were isolated via magnetic bead isolation per product instructions (Invitrogen 
sheep anti-rat Dynabeads, 110.35).  Rat anti-mouse PECAM-1 antibody was 
conjugated to magnetic beads for endothelial cell isolation (BD Pharmingen, 
#553370).  Following isolation, endothelial cells were cultured overnight, then 
treated with 0.1 µg/ml colcemid (Invitrogen, #15210) for 12 hr to halt cells in 
metaphase.  The cells were trypsinized, fixed in 1:3 MeOH: acetic acid and 
analyzed for chromosome number.  Chromosome analysis was performed by 
KaryoLogic, Inc. of Research Triangle Park, NC, according to published 
protocols.29 
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Scratch wound assay 
Cells exposed to low or high VEGF for 10 d were grown to ~80% confluency 
and a 1/8 inch scratch was made in the middle of the dish.  Twenty-four hrs later, 
cells were fixed and centrosomes were antibody labeled as described above.  
Centrosome numbers in the cells at the leading edge of the migrating front were 
compared to centrosome numbers in “static” cells that were distant from the 
leading edge. 
 
Statistical Analysis 
The two-tailed Fisher’s Exact Test was used to determine statistical 
significance in all cases.  Error bars represent standard deviation between 
experiments. 
 
C.  Results 
High VEGF signaling increases the frequency of endothelial cells with 
excess centrosomes in developing vessels 
Centrosome duplication is tightly regulated by cell cycle cues, and excess 
centrosomes can promote errors in chromosome segregation during mitosis, 
leading to the production of aneuploid daughter cells and aberrant cellular 
behaviors.30,31  During early G1, cells contain a single centrosome, composed of 
a mother-daughter centriole pair surrounded by pericentriolar material.  By the 
G1/S transition, the two centrioles have separated, and each nucleates the 
growth of a new centriole.  Centriole growth continues through S phase and early 
G2.  At the onset of mitosis, centrosomes move to opposite ends of the cell and 
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initiate the formation of a bipolar spindle.  After cytokinesis, each daughter cell 
contains one centrosome.  Thus, cells containing greater than one centrosome in 
G1 or greater than two centrosomes thereafter have excess centrosomes (Fig. 
2.1A).3 
Murine endothelial cells isolated from xenograft tumors have an increased 
frequency of excess centrosomes, but the reason for this is unclear.6  Because 
tumor vessels are often exposed to high levels of angiogenic factors such as 
VEGF secreted from tumor cells, we hypothesized that the presence of excess 
centrosomes in tumor endothelial cells not unique to tumor endothelial cells, but 
is a general consequence of elevated VEGF signaling.  Thus we asked whether 
loss of the VEGF receptor flt-1 led to excess centrosomes in endothelial cells of 
developing vessels, because flt-1-/- vessels experience increased VEGF 
signaling.17-19  We first counted centrosome numbers in WT and flt-1-/- mutant 
vessels that form during mouse embryonic stem (ES) cell differentiation.  
Pluripotent ES cells induced to differentiate give rise to a variety of cell types, 
including 3-dimensional, lumenized vessels in a VEGF signaling context that 
mimics developmental scenarios.23,32  Differentiated flt-1-/- ES cell cultures 
displayed dramatic vascular overgrowth compared to WT ES cell cultures, and 
we observed endothelial cells with excess centrosomes in flt-1-/- ES cell-derived 
vessels (Fig. 2.2A-D).  To rigorously score centrosome numbers in ES cell-
derived endothelial cells, we dissociated differentiated ES cell cultures carrying a 
H2B::eGFP transgene linked to a PECAM-1 enhancer-promoter that is 
expressed in endothelial cells.24  After a short attachment period, centrosomes 
were labeled with anti-γ-tubulin, and centrosome numbers in H2B::eGFP-
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expressing cells were quantified.  Anti-γ-tubulin antibody co-localized with several 
distinct centrosomal markers in endothelial cells, confirming the specificity of the 
staining (Fig. 2.1B-J).  We found that endothelial cells from flt-1-/- ES cell-derived 
vessels had a significantly increased frequency of excess centrosomes 
compared to endothelial cells from WT vessels (Fig. 2.2E-G).  
We next sought to determine if flt-1-/- vessels had excess centrosomes in vivo.  
We counted centrosomes in endothelial cells of WT and flt-1-/- yolk sac vessels at 
embryonic day 9.5 (E9.5).  Like flt-1-/- mutant ES cell-derived vessels, flt-1-/- yolk 
sac vessels display dysmorphogenesis and a vascular overgrowth phenotype.14  
Consistent with our findings in ES cell-derived vessels, in vivo flt-1-/- mutant yolk 
sac vessels had significantly more endothelial cells with excess centrosomes 
than WT vessels (Fig. 2.2H-J).  Together, these data show that loss of flt-1 
results in an increased frequency of endothelial cells with excess centrosomes. 
Because flt-1-/- endothelial cells experience abnormally high VEGF signaling, 
we hypothesized that elevated VEGF signaling promotes mis-regulation of 
centrosome duplication in endothelial cells.  We directly assessed the effects of 
elevated VEGF signaling on endothelial cells by culturing human umbilical vein 
endothelial cells (HUVEC) in low VEGF (Endothelial Growth Medium-2, Lonza 
Group Ltd.) or high VEGF (EGM-2 + 200 ng/mL VEGF165) for 4 days, followed 
by centrosome number analysis.  We found that treatment of HUVEC with high 
VEGF resulted in a significant increase in the frequency of cells with greater than 
two centrosomes compared to low VEGF-treated controls (Fig. 2.2K-M).  These 
data are consistent with a model whereby elevated VEGF signaling, due to either 
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loss of flt-1 or exposure to excess VEGF, leads to excess centrosomes in 
proliferating endothelial cells. 
To determine whether the observed centrosome phenotype was unique to 
elevated VEGF signaling, or a more general feature of elevated angiogenic factor 
signaling, we assessed centrosome duplication in the presence of elevated 
Fibroblast Growth Factor-2 (FGF-2).  HUVEC incubated in high FGF-2 had a 
significant increase in the frequency of cells with excess centrosomes that was 
similar to the frequency seen with high VEGF treatment (Fig. 2.3A).  However, 
incubation in both high VEGF and high FGF-2 did not lead to a further increase in 
the frequency of endothelial cells with excess centrosomes, suggesting that the 
growth factor effects are not additive.  Since both growth factors activate similar 
signaling pathways in endothelial cells, this result indicates that these pathways 
are likely activated at maximum capacity with the addition of one growth factor. 
 
The VEGF-induced excess centrosome phenotype in endothelial cells is 
not downstream of elevated proliferation or cytokinesis defects  
To begin to determine the mechanism(s) responsible for the VEGF-induced 
centrosome over-duplication phenotype, we first determined whether HUVEC 
exposed to high VEGF proliferated more during the time course than controls, 
since more cell cycle transits might produce centrosome defects in a non-specific 
manner.  The number of cell doublings was independent of VEGF levels over the 
time course.  Cells divided every 26.5 hr on average in low VEGF and every 26.2 
hr on average in high VEGF, suggesting that the number of centrosome 
duplication cycles that occurred during the time course was equivalent in the two 
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treatments (Fig. 2.3B).  “Low VEGF” is the manufacturers recommended medium 
to support HUVEC growth and expansion, so it is likely that endothelial cell 
division is optimized under these conditions.  These results show that the excess 
centrosome defect observed in high VEGF-treated endothelial cells is not due to 
increased cell proliferation, and they suggest that the elevated VEGF levels in 
“high VEGF” treatment selectively affect centrosome numbers.  
We reasoned that excess centrosomes could result from direct mis-regulation 
of pathways that regulate centrosome duplication, or they could be downstream 
of a cytokinesis defect.  Failure to complete cytokinesis during cell division leads 
to daughter cells with two centrosomes that duplicate in the next S phase to 
produce cells with 4 centrosomes.  To test whether high VEGF signaling 
promotes incomplete cytokinesis in endothelial cells, we analyzed DNA content 
in HUVEC incubated in low or high VEGF conditions, because polyploidy is an 
expected consequence of incomplete cytokinesis.  FACS sorting for DNA content 
showed that high VEGF-treated cells had similar levels of polyploid cells 
compared to low VEGF-treated cells (Fig. 2.4A-B).  We also analyzed the 
distribution of centrosome number in endothelial cells with greater than two 
centrosomes, as incomplete cytokinesis is predicted to result in a preponderance 
of aberrant cells with 4 centrosomes.  We found that centrosome number 
distribution in high VEGF treated endothelial cells with greater than two 
centrosomes peaked at 3 centrosomes and was not skewed to 4 centrosomes 
(Fig. 2.4C).  Taken together, our findings suggest that high VEGF-treated 
endothelial cells do not acquire excess centrosomes as a result of incomplete 
cytokinesis. 
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High VEGF signaling promotes endothelial centrosome over-duplication via 
hyper-activation of cyclin E/Cdk2 
To test the hypothesis that abnormally high VEGF signaling directly promotes 
mis-regulation of centrosome duplication in endothelial cells, we investigated 
signaling downstream of VEGF in HUVEC.  Cyclin E/Cdk2 activity initiates 
centrosome duplication beginning at the G1/S cell cycle transition, and 
abnormally high levels are associated with centrosome over-duplication in other 
cell types.33-37  Cyclin E/Cdk2 phosphorylates Nucleophosmin-1 (NPM) at the 
centrosome, and this phosphorylation is required for the initiation of centrosome 
duplication.38  However, upstream signaling factors that feed into this pathway 
have not been elucidated.  To determine whether increased cyclin E/Cdk2 
activity in endothelial cells is responsible for VEGF-induced centrosome over-
duplication, we first examined cyclin E levels.  HUVEC were serum-starved to 
synchronize the cells in a G1-like arrest, then exposed to low or high VEGF 
conditions for 12 hr, because at that time the synchronized cells are at the G1/S 
transition that signals the onset of centrosome duplication (data not shown).  We 
found increased levels of cyclin E protein in high VEGF-treated endothelial cells 
relative to low VEGF-treated cells (Fig. 2.5A).  To determine whether the 
increase in cyclin E levels was accompanied by an increase in cyclin E/Cdk2 
activity, we analyzed Cdk2 activity.  Cdk2 was isolated by immunoprecipitation 
from the same lysates used to quantify cyclin E levels, and its ability to 
phosphorylate histone H1 in an immune-complex kinase assay was assessed.  
Cdk2 activity was elevated in high VEGF-treated endothelial cells relative to 
controls, at the 12 hr time point and at earlier and later time points as well (Fig. 
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2.5B and data not shown).  These data show that abnormally high VEGF 
signaling leads to elevated cyclin E/Cdk2 activity in endothelial cells. 
To determine if the increase in cyclin E levels induced by elevated VEGF 
signaling is required for mis-regulation of centrosome duplication in endothelial 
cells, we reduced cyclin E levels in high VEGF-incubated HUVEC using 
lentivirus-delivered shRNA.  Cells were cultured in high VEGF for 96 hr after 
infection with either cyclin E shRNA virus or empty vector control.  High VEGF 
incubation for 96 hr increased cyclin E protein levels, similar to the 12 hr analysis 
described above, and cyclin E shRNA infection reduced cyclin E protein levels in 
high VEGF-treated HUVEC to approximately the levels seen in low VEGF-treated 
cells (Fig. 2.5D).  HUVEC incubated in high VEGF with reduced cyclin E levels 
had a reduced frequency of endothelial cells with excess centrosomes relative to 
incubation with high VEGF and elevated cyclin E levels (Fig. 2.5E).  These data 
show that elevated cyclin E levels downstream of abnormally high VEGF 
signaling contribute substantially to centrosome over-duplication in endothelial 
cells, and they suggest that elevated cyclin E/Cdk2 activity is responsible for the 
VEGF-induced mis-regulation of endothelial centrosome duplication. 
Increased cyclin E/Cdk2 activity results in increased NPM phosphorylation at 
Serine-199 in other cell types.  This modification initiates centrosome duplication 
by promoting translocation of NPM from the centrosome, where it inhibits 
centrosome duplication, to the nucleus.38  Analysis of NPM phosphorylation in 
HUVEC following serum-starvation and incubation in low or high VEGF for 12 hr 
showed that P-NPM (Ser199) levels were elevated in high VEGF-treated cells 
relative to controls (Fig. 2.5C).  Taken together, these results are consistent with 
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a model whereby abnormally high VEGF signaling leads to increased cyclin E 
levels and cyclin E/Cdk2 hyper-activation, which in turn leads to increased P-
NPM and centrosome over-duplication. 
 
MEK/ERK and AKT promote cyclin E accumulation and centrosome over-
duplication downstream of elevated VEGF signaling 
We next investigated signaling between the initial VEGF signal and the cyclin 
E/Cdk2 hyper-activity that promotes centrosome over-duplication in endothelial 
cells.  VEGF activates a MEK/ERK signaling cascade, and MEK/ERK signaling 
promotes cyclin E accumulation in other cell types.39,40  Thus we hypothesized 
that elevated VEGF signals through MEK/ERK to elevate cyclin E levels and 
promote centrosome over-duplication in endothelial cells.  We assessed ERK1/2 
phosphorylation in HUVEC as a proxy for ERK activation, after serum-starvation 
and exposure to low or high VEGF for 5 min, and found that P-ERK levels were 
increased in high VEGF-treated cells relative to controls (Fig. 2.6A).  Next, we 
asked whether MEK inhibition rescued centrosome over-duplication.  HUVEC 
incubated in high VEGF with a MEK inhibitor (U0126) had reduced P-ERK 
activation, reduced cyclin E levels, and significantly rescued centrosome 
numbers relative to HUVEC incubated in high VEGF without inhibitor (Fig. 2.6A-
C).  Thus MEK inhibition rescued pathway hyper-activation induced by high 
VEGF and also rescued the centrosome over-duplication defect, indicating that 
MEK/ERK signaling downstream of VEGF activation contributes to mis-regulation 
of centrosome duplication in endothelial cells. PKC also acts downstream of 
VEGF to promote ERK activation, and treatment with a PKC inhibitor also 
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partially rescued high VEGF-induced centrosome over-duplication (Fig. 2.7). 
High FGF treatment also lead to elevated ERK activation and cyclin E levels, 
suggesting that FGF also promotes centrosome over-duplication via signaling 
through MEK/ERK to cyclin E (Fig. 2.8). 
AKT is a second signaling arm downstream of VEGF that also affects cyclin E 
levels.40-42  To determine whether elevated AKT activity downstream of VEGF 
signaling in endothelial cells also contributes to centrosome over-duplication, 
HUVEC were serum-starved and treated with low or high VEGF for 1 hr, then 
AKT phosphorylation was assessed.  We found elevated P-AKT in high VEGF-
treated HUVEC (Fig. 2.6B).  Additionally, HUVEC were incubated in high VEGF 
with an AKT inhibitor (1L-6-Hydroxymethyl-chiro-inositol 2-(R)-O-methyl-3-O-
oxtadecylcarbonate).  AKT inhibitor treatment significantly reduced cyclin E levels 
and the percentage of cells with excess centrosomes relative to high VEGF-
treated HUVEC without inhibitor (Fig. 2.6C-D).  As predicted, activated ERK 
levels induced by high VEGF treatment were not affected by treatment with AKT 
inhibitor (Fig. 2.6A), suggesting that VEGF signaling through AKT to cyclin E 
represents an additional mechanism whereby VEGF modulates centrosome 
duplication in endothelial cells. We also asked if VEGF signals through p38 
MAPK to affect centrosome number, and found that 96 hr incubation in high 
VEGF + p38 MAPK inhibitor did not rescue centrosome number, suggesting that 
VEGF does not signal through p38 MAPK to affect centrosome duplication (Fig. 
2.7).  Taken together, these data suggest that VEGF signals through both 
MEK/ERK and AKT to promote cyclin E/Cdk2 hyper-activity and centrosome 
over-duplication in endothelial cells.  
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Endothelial cells containing excess centrosomes survive and divide, and 
display aneuploidy and increased migration  
To begin to assess the biological consequences of centrosome over-
duplication, we examined whether endothelial cells containing excess 
centrosomes survived or underwent programmed cell death.  High VEGF-treated 
HUVEC were stained for centrosomes and activated caspase 3, a marker of 
apoptotic cells.  Although control cells with 4-hydroxynonenal (HNE)-induced 
apoptosis were positive for activated caspase 3, there was no detectable 
activated caspase 3 reactivity in HUVEC with excess centrosomes (0/15 cells 
with excess centrosomes were activated caspase-3 positive) (Fig. 2.9A-H).  We 
also analyzed the frequency of endothelial cells with excess centrosomes as a 
function of exposure time to high VEGF, reasoning that significant “drop-out” 
would result in a constant percentage over time, while survival of endothelial cells 
with excess centrosomes would lead to increased percentages over time.  A 
significantly higher percentage of endothelial cells had excess centrosomes 
when treated for 240 hr in high VEGF compared to the normal 96 hr treatment 
(Fig. 2.9M).  These data indicate that endothelial cells with excess centrosomes 
do not undergo apoptosis at significant frequencies. 
We next asked whether endothelial cells with excess centrosomes were 
capable of cell division, since mitosis in the presence of excess centrosomes can 
lead to aneuploidy.30,31,43  Examination of high VEGF-treated HUVEC revealed 
examples of bi-polar spindle formation (Fig. 2.9I-J).  While cells with 2 
centrosomes had normal spindles (Fig. 2.9I), cells with excess centrosomes 
displayed aberrant spindles (Fig. 2.9J). The cells with excess centrosomes are 
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predicted to complete mitosis but have an increased probability of aneuploidy 
due to uneven pulling forces from the spindles.31,43  We also observed mitotic 
endothelial cells with multipolar spindles (Fig. 2.9K-L).  These cells are also 
predicted to complete mitosis with high frequency but with gross aneuploidy as a 
result of having more than two spindles.   
Since endothelial cells with excess centrosomes survive and divide, we 
hypothesized that developing vessels containing endothelial cells with excess 
centrosomes would also exhibit increased levels of aneuploidy.  Thus we 
assayed endothelial cells isolated from ES cell-derived vessels for chromosome 
number.  As predicted, flt-1-/- endothelial cells isolated from ES cell-derived 
vessels, which had excess centrosomes, also displayed increased aneuploidy 
(average 48 chromosomes/cell, normal=40) compared to endothelial cells 
isolated from WT vessels (average 42 chromosomes/cell) (Fig. 2.10A-C).   Flt-1-/- 
endothelial cells also had chromosomal aberrations, including chromosome 
breaks and triradials, that were not detected in WT endothelial cells (Fig. 2.10B).  
These results suggest that vessels containing endothelial cells with excess 
centrosomes accumulate aneuploid cells that contribute to vessel dysfunction.  
 
Endothelial cells that contain excess centrosomes are enriched at in vitro 
scratch wounds 
We hypothesized that excess centrosomes might affect additional endothelial 
cell functions.  Because centrosomes are the microtubule organizing centers in 
cells, and microtubules play a critical role in migration, we wondered if excess 
centrosomes would perturb endothelial cell migration.  Thus we performed a 
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scratch/wound assay to assess migration in endothelial cells with excess 
centrosomes.  To our surprise, endothelial cells at the leading migratory front had 
a higher frequency of excess centrosomes compared to cells that were distant 
from the migratory front (Fig. 2.11).  The differences were significant for low 
VEGF treated endothelial cells, and the same trends were seen with high VEGF 
treatment (Fig. 2.11C).  These data suggest that centrosome over-duplication 
leads to abnormal migration in endothelial cells by increasing their migratory 
capacity. 
 
D.  Discussion 
 
Our work demonstrates that elevated angiogenic factor signaling promotes 
centrosome over-duplication in the endothelial cells of developing vessels, and it 
provides a mechanistic understanding of this phenotype.  We also show that 
endothelial cells with excess centrosomes are not restricted to tumor vessels, but 
are a hallmark of vessels exposed to elevated VEGF signaling in several 
contexts, and are associated with aberrant cell divisions and aneuploidy.  Thus, 
mis-regulation of centrosome duplication is a novel aspect of de-regulated 
angiogenic factor signaling that impacts the phenotype and potentially the 
function of endothelial cells in blood vessels. 
Developing vessels lacking flt-1 function have an elevated frequency of 
endothelial cells with aberrant centrosome numbers in both ES cell-derived 
vessels and in vivo, in the developing vessels of the embryonic yolk sac.  These 
vessels also have an elevated mitotic index, suggesting that flt-1 mutant 
endothelial cells have a shorter cell cycle progression time relative to WT 
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endothelial cells.15  It is possible that a low “normal” frequency of centrosome 
over-duplication is amplified in the flt-1 mutant background due to this 
acceleration of the cell cycle.  However, the difference in mitotic indices between 
WT and flt-1-/- endothelial cells is small (1.4% (WT) vs. 2.8% (flt-1-/-) for yolk sac 
endothelial cells15) relative to the difference in the frequency of endothelial cells 
with excess centrosomes (0% (WT) vs. 11% (flt-1-/-), this study), suggesting that 
centrosome over-duplication in endothelial cells of flt-1-/- developing vessels is 
not solely a consequence of an accelerated cell cycle.  Moreover, we 
demonstrate a significant increase in centrosome over-duplication in HUVEC 
exposed to elevated VEGF signaling, that is not accompanied by an overall 
increase in doubling time.  These findings indicate that mis-regulation of 
centrosome duplication is a primary effect of abnormally high VEGF signaling. 
Elucidation of signaling downstream of VEGF that promotes centrosome 
over-duplication in endothelial cells provides a mechanistic basis for the 
phenotype, and it also supports a model whereby aberrant centrosome numbers 
are a direct effect of perturbed VEGF signaling.  We show that downstream of 
elevated VEGF, both MEK/ERK signaling and AKT signaling are elevated, as 
expected from previous studies of VEGF signaling in endothelial cells.40,41  Both 
MEK/ERK and AKT feed into regulation of the cell cycle regulator cyclin E/Cdk2 
activity in other cell types, and cyclin E/Cdk2 is implicated in regulation of 
centrosome duplication.33-37  Thus, we investigated cyclin E/Cdk2 in VEGF-
stimulated endothelial cells and found that both cyclin E levels and Cdk2 activity 
were increased, consistent with a model whereby VEGF signaling exerts a direct 
effect on cyclin E/Cdk2.  Moreover, blockade of any component of these 
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signaling axes downstream of VEGF significantly reduced the VEGF-induced 
centrosome over-duplication defect, showing that these activities are required for 
the phenotype.  Both MEK/ERK and AKT signaling have numerous effects on 
endothelial cells, but the finding that attenuated signaling through either cassette 
also reduced the high VEGF-induced elevated levels of cyclin E suggests that 
direct effects from VEGF through MEK/ERK and AKT to cyclin E/Cdk2 regulate 
centrosome duplication in endothelial cells (Figure 2.12). Blockade of PKC, but 
not p38 MAPK, also partially rescued centrosome number, suggesting that 
several, but not all, signaling cassettes downstream of VEGF affect centrosome 
over-duplication in endothelial cells.  Phosphorylation of the centrosome-
associated protein NPM downstream of cyclin E/Cdk2 occurs in high VEGF-
stimulated endothelial cells, and this phosphorylation can affect centrosome 
duplication.38  The microtubule-binding protein ninein has a complex localization 
pattern in endothelial cells that is regulated by phosphorylation downstream of 
VEGF,44 so it may also be a downstream effector of VEGF effects on 
centrosomes.  FAK mutant endothelial cells or endothelial cells expressing Ser-
732-mutated FAK protein were reported to have excess centrosomes,45 
suggesting that both proper adhesion to substrates and VEGF signaling are both 
important for regulation of centrosome numbers in endothelial cells. 
What are the consequences of aberrant centrosome numbers in endothelial 
cells of developing vessels?  Endothelial cells with excess centrosomes as a 
result of elevated VEGF signaling do not undergo apoptosis; rather, they appear 
to survive and accumulate.  Moreover, we demonstrate that endothelial cells with 
excess centrosomes can form aberrant spindles during mitosis, an abnormality 
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that is predicted to lead to endothelial aneuploidy.  Consistent with this 
hypothesis, endothelial cells isolated from flt-1-/- mutant developing vessels that 
experienced elevated VEGF signaling had an increased frequency of aneuploidy, 
as assayed by abnormal chromosome number, and they also had chromosome 
breaks and triradials, which result from asymmetrical sister chromatid exchange. 
The centrosome clustering and multipolar spindle formation that result from 
excess centrosomes are predicted to induce chromosome gain and/or loss as 
well as chromosome breaks at mitosis due to unequal pulling forces on the 
chromosomes, so the cytogenetic abnormalities seen in endothelial cells from flt-
1-/- mutant vessels likely result from the increased frequency of excess 
centrosomes.  Our data also provides a mechanism for the finding that isolated 
tumor endothelial cells, which presumably experience elevated VEGF signaling, 
have an increased frequency of excess centrosomes and elevated levels of 
aneuploidy.5,6  We predict that aneuploid endothelial cells are likely to contribute 
to the aberrant vascular phenotypes associated with elevated VEGF signaling, 
via gain or loss of chromosomes that encode genes involved in proliferation, 
migration, and cell-cell adhesion.  Endothelial cells with excess centrosomes are 
also enriched at the leading edge of in vitro scratch wounds, suggesting that they 
might migrate more rapidly than normal endothelial cells, and this cellular 
phenotype may also contribute to vessel dysfunction. 
Our work has implications for regulation of angiogenesis in non-
developmental contexts.  Elevated VEGF signaling is associated with aberrant 
angiogenesis in several pathologies, such as diabetes and cancer.  Moreover, 
tumors express numerous growth factors, and elevated FGF also leads to over-
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duplication of centrosomes in endothelial cells.  Tumor vessels differ substantially 
from normal vessels – they are tortuous in phenotype and leaky in function, and 
thus poor at oxygen delivery.46-48  Additionally, endothelial cells isolated from 
some tumors appear to be more “progenitor-like”, and capable of differentiating 
into other mesodermal lineages.49  It is tempting to speculate that the introduction 
of aneuploidy downstream of centrosome duplication defects contributes to these 
changes.  In any case, our demonstration of a clear link between VEGF signaling 
and centrosome duplication in endothelial cells of developing vessels suggests 
that this cellular phenotype contributes to the aberrant angiogenesis that 
accompanies elevated VEGF signaling. 
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Figure 2.1.  Centrosomes duplicate once per cell cycle and can be 
visualized in endothelial cells.  (A) Diagram of the cell cycle and centrosome 
duplication cycle.  (B-G) HUVEC were fixed and stained for centrosome markers 
in endothelial cells: (B-D) γ-tubulin (red) co-localizes with Pericentrin (green).  (E-
G) γ-tubulin (red) co-localizes with Nucleophosmin-1 (NPM, green).  DNA is 
labeled with DRAQ5 (blue).  Arrowheads point to co-localization.  Scale 
bar=5µm. 
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Figure 2.2.  High VEGF signaling leads to an increased frequency of excess 
centrosomes in endothelial cells of developing vessels.  (A-B) Day 8 ES cell-
derived wildtype (WT) and flt-1-/- mutant vessels were stained for PECAM-1 (red); 
note the vessel overgrowth and dysmorphogenesis in panel B.  (C-J) Endothelial 
cells of WT and flt-1-/- mutant vessels were analyzed for centrosome numbers.  
(C-D) Day 8 ES cell cultures were fixed and stained for γ-tubulin (red), PECAM-1 
(green) and DRAQ5 nuclear dye (blue).  (F-G) Day 8 ES cell cultures that were 
WT or flt-1-/- and carried a PECAM-H2B::GFP transgene (green) were dissociated 
and attached to tissue culture dishes prior to fixation and staining for γ-tubulin 
(red).  (E) Percentage of PECAM-H2B::GFP positive cells with >2 centrosomes 
(WT, n=159; flt-1-/-, n=336).  (I-J) WT and flt-1-/-  embryos were harvested at E9.5, 
and yolk sacs were stained for γ-tubulin (red), PECAM-1 (green) and DRAQ5 
nuclear dye (blue).  (H) Percentage of PECAM positive yolk sac endothelial cells 
with >2 centrosomes (WT, n=88; flt-1-/-, n=180).  (L-M) HUVEC were incubated 
for 96 hr in low or high VEGF, then stained for γ-tubulin (red) and DRAQ5 
nuclear dye (blue).  (K) Percentage of HUVEC with >2 centrosomes (low VEGF, 
n=2393; high VEGF, n=3011).  Arrows point to areas of cells with >2 
centrosomes, and arrowheads point to areas of cells with 1-2 centrosomes.  
Insets (panels D, I, J, M) show centrosomes at higher magnification.  All 
experiments were performed at least three times.  Scale bar = 50 µm (A-B); 5 µm 
(C-M). *, p<0.05; ***, p<0.0001, low VEGF vs. high VEGF. 
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Figure 2.3.  VEGF and FGF increase the frequency of excess centrosomes 
in endothelial cells independent of proliferative changes.  (A) Percentage of 
HUVEC with >2 centrosomes in indicated conditions (low VEGF/low FGF, 
n=1594; high VEGF, n=1717; high FGF, n=1563; high VEGF/high FGF, n=866).  
**,p<0.001; ***,p<0.0001 vs. low VEGF/low FGF.  (B) HUVEC growth curves in 
low and high VEGF, expressed as fold increase in cell number relative to t=0.   
Blue line, low VEGF conditions; red line, high VEGF conditions.  All experiments 
were performed at least 3 times. 
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Figure 2.4.  The high VEGF-induced excess centrosome defect does not 
correlate with incomplete cytokinesis.  (A-B) Fluorescence activated cell 
sorting (FACS)-generated cell cycle profiles of HUVEC treated for 96 hr in low 
(A) or high (B) VEGF and labeled with propidium iodide (G0/G1, S and G2/M 
represent cell cycle phases; Poly represents polyploid cells).  (C) Distribution of 
centrosome number in HUVEC containing >2 centrosomes following high VEGF 
treatment.  All experiments were performed at least 3 times. 
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Figure 2.5.  VEGF signals through cyclin E/Cdk2 to promote mis-regulation 
of centrosome duplication in endothelial cells.  (A-C) HUVEC were serum 
starved, then treated for 12 hr with low or high VEGF. (A) Western blot of lysates 
hybridized with anti-cyclin E, normalized to actin.  (B) Autoradiogram of Cdk2 
immune-complex kinase assay normalized to total Cdk2 immunoprecipitation 
(IP).   (C) Western blot of lysates hybridized with anti-P-NPM, normalized to total 
NPM.  (D-E) HUVEC were infected with empty vector (EV) or cyclin E shRNA 
(CycE KD) lentivirus for 6 hr, then incubated in low or high VEGF for 96 hr.  (D) 
Western blot of lysates hybridized to anti-cyclin E and normalized to actin.  (E) 
Following lentiviral infection and VEGF treatment, cells were fixed, stained for -
tubulin and DRAQ5, and centrosome numbers were counted (low VEGF, n=656; 
high VEGF, n=750; high VEGF + empty vector (EV), n=717; high VEGF + cyclin 
E knockdown (CycE KD), n=696).  All experiments were performed at least 3 
times.  ***, p<0.0001 vs. low VEGF; #, p<0.05 vs. high VEGF. 
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Figure 2.6.  VEGF signals through MEK/ERK and AKT to mis-regulate 
centrosome duplication in endothelial cells.  HUVEC were serum starved, 
then incubated with low or high VEGF. (A) HUVEC treated for 5 min without 
inhibitor or with U0126 (MEKI) or 1L-6-Hydroxymethyl-chiro-inositol 2-(R)- O-
methyl-3-O-oxtadecylcarbonate (AKTI) were lysed, hybridized to anti-P-ERK and 
normalized to total ERK2.  (B) HUVEC treated with low or high VEGF for 1 h 
were lysed, hybridized to anti-P-AKT and normalized to total AKT. (C) HUVEC 
treated with indicated levels of VEGF for 12 hr without inhibitors or with MEKI or 
AKTI were lysed, hybridized to anti-cyclin E and normalized to actin.  (D) HUVEC 
treated with indicated levels of VEGF for 96 hr without inhibitors or with MEKI or 
AKTI were fixed, stained for γ-tubulin and DRAQ5, and centrosome numbers 
were counted (low VEGF, n=1036; high VEGF, n=1369; high VEGF + MEKI, 
n=1152; high VEGF + AKTI, n=586).  All experiments were performed at least 3 
times.  *, p<0.05 vs. low VEGF; **, p<0.001 vs. low VEGF; ***, p<0.0001 vs. low 
VEGF; #, p<0.05 vs. high VEGF; ##, p<0.001 vs. high VEGF. 
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Figure 2.7. VEGF signals through PKC but not p38 MAPK to promote 
centrosome over-duplication. HUVEC were treated with Low VEGF (EGM-2 
medium), High VEGF (EGM-2 + 200 ng/ml VEGF), High VEGF + p38 MAPK 
Inhibitor (p38I) or High VEGF + PKC Inhibitor (PKCI) for 12 hr following serum 
starvation (A) or 96 hr (B). A) Western blot analysis of cyclin E levels relative to 
total actin. B) Bar graph showing % cells with excess (>2) centrosomes following 
96 hr of the indicated treatments. *,p<0.05 vs. 96 hr low VEGF; **,p<0.001 vs. 96 
hr low VEGF; #, p<0.05 vs. 96 hr high VEGF. 
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Figure 2.8. High VEGF or FGF signaling leads to elevated ERK activation 
and cyclin E levels. HUVEC were serum-starved for 12 hr, then treated with 
Low VEGF (EGM-2 medium), High VEGF (EGM-2 + 200 ng/ml VEGF) or High 
FGF (EGM-2 + 200 ng/ml FGF-2) for 5 min (P-ERK) or 12 hr (cyclin E). A) 
Western blot analysis of ERK phosphorylation relative to total ERK2. B) Western 
blot analysis of cyclin E levels relative to total actin.  Data are representative of at 
least 3 experiments. 
  
59 
 
 
60 
 
Figure 2.9.  Mis-regulation of centrosome duplication does not lead to 
apoptosis in endothelial cells.  (A-H) HUVEC were stained with anti-activated 
caspase 3 (red), pericentrin (green) and DRAQ5 nuclear dye (blue) following 
treatment with high VEGF for 96 hr, with (A-D) or without (E-H) the apoptosis-
promoting drug HNE for the final 48 hr.  Inset in F shows centrosomes at higher 
magnification.  HNE-treated cells were positive for activated caspase 3, but high 
VEGF-treated HUVEC containing excess centrosomes did not stain for activated 
caspase 3.  (I-L) HUVEC were stained with anti-pericentrin (green), anti-α-tubulin 
(red) and DRAQ5 to visualize mitotic figures.  Bipolar spindles containing 2 
centrosomes (I) or >2 centrosomes (I-J) were observed in addition to multipolar 
spindles (K-L) containing >2 centrosomes.  (M) HUVEC were incubated with low 
or high VEGF for the indicated times, then fixed and stained for γ-tubulin and 
DRAQ5 for centrosome counts (96 hr low VEGF, n=890; 240 hr low VEGF, 
n=976; 96 hr high VEGF, n=1023; 240 hr high VEGF, n=897).  All experiments 
were performed at least 3 times.  Scale bar = 5µm. **,p<0.001 vs. 96 hr low 
VEGF; ***, p<0.0001 vs. 96 hr low VEGF; #, p<0.05 vs. 96 hr high VEGF. 
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Figure 2.10.  VEGF gain-of-function flt-1-/- endothelial cells from developing 
vessels display aneuploidy and chromosome aberrations.  Endothelial cells 
from WT and flt-1-/- ES cell-derived vessels were isolated via magnetic bead 
isolation and analyzed for chromosome number and abnormalities.  (A-B) 
Giemsa stained WT (A) and flt-1-/- (B) endothelial cell metaphase spreads with 40 
and 47 chromosomes (CS), respectively (M. musculus 2n=40). Arrows in B point 
to abnormal tri-radial chromosome configurations. (C) Scatter plot showing 
chromosome number in WT vs. flt-1-/- endothelial cells from developing vessels.  
Each dot represents one cell, red dots represent cells with 40 CS, blue dots 
represent aneuploid cells.  WT, n=25; flt-1-/-, n=25.  Experiments were performed 
in triplicate.  *p≤0.05. 
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Figure 2.11.  Endothelial cells with excess centrosomes are enriched at the 
leading edge of a scratch wound.  HUVEC were incubated for 10 d in low or 
high VEGF.  Then a scratch wound was made 24 hr. prior to analysis.  Cells 
were stained for α-tubulin (C,G), pericentrin (D,H) and the DNA dye DRAQ5 (E,I). 
(A) Cells at the leading edge of a scratch wound in high VEGF treated cells; 
single cells in insets (a) and (b) have excess centrosomes and are imaged at 
higher magnification in (C-F) and (G-J), respectively.  Insets in (D) and (H) are 
zoomed-in images of centrosomes. (B) Quantification of centrosome numbers at 
the “migratory” leading edge vs. “static” cells away from the edge in the indicated 
conditions (low VEGF static, n=354; low VEGF leading edge, n=338; high VEGF 
static, n=307; high VEGF leading edge, n=293).  All experiments were performed 
at least 3 times.  (F) and (J) are merged images of (C-E) and (G-I), respectively 
(α-tubulin, red; pericentrin, green; DRAQ5, blue). Scale bar = 5mm.  ***, 
p≤0.0001 vs. low VEGF static. 
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Figure 2.12.  Model for VEGF regulation of endothelial centrosome 
duplication.  A schematic of proposed signaling to regulate centrosome 
duplication in endothelial cells.  In this model, VEGF promotes MEK/ERK and 
AKT signaling, leading to increased levels of cyclin E.  Cyclin E binds Cdk2 to 
activate cyclin E/Cdk2 activity and promote centrosome duplication, perhaps via 
phosphorylation of NPM.  Elevated VEGF levels lead to abnormally high 
Cdk2/cyclin E activity and centrosome over-duplication. 
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CHAPTER III 
ORIENTATION OF ENDOTHELIAL CELL DIVISION IS REGULATED BY VEGF 
SIGNALING DURING BLOOD VESSEL FORMATION 
 
 
 
This work was performed in collaboration with Dr. Gefei Zeng, a former 
Bautch lab post-doctoral researcher, among others.  Susan Whitfield of the UNC 
Biology Department made the image in Fig. 3.1.  Gefei performed the 
experiments described in Figs. 3.2, 3.3, and 3.6.  Gefei analyzed movies 
produced by Joe Kearney and Nick Kappas, former Bautch lab graduate 
students, for Fig. 3.4.  Gefei and I each performed 50% of the work described in 
Figs. 3.5 and 3.9.  I performed the experiments described in Figs. 3.7 and 3.8.  
All retinal analyses were performed with substantial intellectual input from Jan 
McColm and ME Hartnett at UNC.  The majority of this work was published in 
Blood: 
Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett 
ME and Bautch, VL. Orientation of endothelial cell division is regulated by VEGF 
signaling during blood vessel formation. Blood. 2007;109, 1345-1352. 
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A.  Introduction 
Blood vessels form and expand in both development and disease, via processes 
that include vasculogenesis, angiogenesis, and intussusception.1-3  Sprouting 
angiogenesis is the coordinated migration of groups of endothelial cells from vessels 
and their subsequent fusion to form new interconnections.  In this way, simple 
vascular tubes are ramified and extended to form a primitive vascular plexus.  This 
vessel plexus forms at numerous sites in the embryo, including the yolk sac, the 
head mesenchyme, and surrounding the neural tube.  The primitive vascular plexus 
is then remodeled under the influence of blood flow and interactions with mural cells.  
Thus, the initial pattern of vessels serves as a template for remodeling that leads to 
a mature vasculature.  
 During formation of the primitive vascular plexus, several cellular processes 
must be regulated and integrated.  Specifically, endothelial cells respond to some 
morphogenetic cues by sprouting, while actively dividing to expand the pool of 
endothelial cells.  One level of integration occurs via the signaling pathways that 
promote angiogenesis, as many impact both endothelial cell division and 
morphogenesis.  The VEGF signaling pathway is an example of this mode of 
integration, as it regulates both cell division and branching morphogenesis.4-8  
VEGF-A (VEGF) binds two high affinity receptors on endothelial cells, Flk-1 
(VEGFR-2) and Flt-1 (VEGFR-1), and perturbation of VEGF signaling by genetic 
deletion of either receptor affects both endothelial cell division and morphogenesis.9-
12
  Several lines of evidence, however, suggest that different regulatory nodes in the 
VEGF signaling pathway influence endothelial cell division and morphogenesis.  
VEGF signaling through Flk-1 promotes endothelial cell division through the 
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Raf/MEK/ERK pathway, whereas endothelial cell migration is stimulated through p38 
MAPK and adaptor proteins such as Shb and Nck that lead to regulation of the actin 
cytoskeleton.13-16  Additionally, the overall level of available VEGF is thought to 
regulate the rate of endothelial cell division, while VEGF presentation, perhaps 
through the formation of a gradient, is thought to regulate sprouting angiogenesis 
and the formation of filopodia.11,12,17,18  Moreover, other pathways selectively impact 
endothelial cell division or morphogenesis.  For example, signaling through p27/kip1 
regulates the endothelial cell cycle,19,20 while the netrin-UNC and semaphorin-plexin 
pathways regulate endothelial branching morphogenesis and guidance.21-23  Thus it 
is likely that endothelial cell division and morphogenesis are integrated at multiple 
levels during angiogenesis, but little is known about how this is achieved. 
The orientation of the cleavage plane of cell division, which positions the 
daughter cells relative to other embryonic axes, is regulated in numerous developing 
tissues.24-26  The basis for this regulation is the interaction of the mitotic spindle with 
molecules differentially localized on the inner side of the plasma membrane (the 
cortex).27  The cortical cues include the PAR proteins first identified in C. elegans, 
atypical protein kinases (aPKCs), and molecules such as LGN, NuMA, and 
Inscuteable, that appear to link microtubules to the cortex.28-30  The spatial regulation 
of these cues is complex and not completely understood, but the actin cytoskeleton 
and its interactions with the cortex are required for proper positioning of the cues 
and in turn the mitotic spindle.31  The actin cytoskeleton in turn is acted upon by 
numerous inputs, among them growth factor signaling.  
Complex structures such as epithelial sheets and tubes can exhibit a polarity of 
division orientation.32-34  MDCK cells form tubes in culture in response to hepatocyte 
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growth factor (HGF)/scatter factor signaling, and this signaling can re-orient MDCK 
cell divisions so that daughter cells leave the epithelial sheet.35,36  Kidney tubules 
expand via cell divisions that are oriented to extend the length of the tubule.37  
Epidermal cleavages oriented parallel to the long axis of the sheet resulted in 
daughter cells that formed a new layer during embryonic skin development, and loss 
of several pathways, including those involving β1 integrins, lead to increased 
randomization of divisions and aberrant stratification.29  Oriented cell divisions are 
also associated with flower bud formation, elongation of the avian primitive streak, 
shaping of the neural plate in avians and mouse, and extension of the zebrafish 
body axis at gastrulation.38-42 
Endothelial cells orient their actin cytoskeleton and microtubule network in 
response to shear stress, such as that produced by blood flow in vivo.43-45  However, 
despite the fact that endothelial cells actively divide while undergoing 
morphogenesis, the orientation of endothelial cell cleavages during normal and 
perturbed angiogenesis has not been investigated.  We asked whether the 
orientation of endothelial division was regulated in a flow-independent model of 
dynamic angiogenesis in culture and in retinal vessels in vivo.  Here we show that 
endothelial cell cleavage is normally oriented perpendicular to the long axis of the 
vessel, which can promote vessel lengthening, a hallmark of these expanding 
vascular plexuses.   Moreover, we show that orientation is randomized by a mutation 
that disrupts VEGF signaling and leads to vessel dysmorphogenesis, and it is 
rescued by genetic rescue of the mutation.  These data indicate that endothelial cell 
division orientation is regulated by flow-independent morphogenetic cues, and that 
endothelial cell division is normally oriented by a process that involves VEGF 
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signaling.  Our findings also suggest that the integration of proliferative and 
morphogenetic processes is critical to proper vessel morphogenesis.   
 
B.  Materials and methods 
Cell culture and in vitro differentiation 
Embryonic stem (ES) cell lines used consisted of wild-type (WT; +/+) and flt-1-
/-
 ES cells containing a transgene consisting of enhanced green fluorescent 
protein (eGFP) fused to histone 2B (H2B) under the transcriptional control of the 
platelet endothelial cell adhesion molecule (PECAM) promoter/intron enhancer 
element (Tg PECAM-H2B-GFP),(12 and this report) as well as WT ES cells containing  
a PECAM-eGFP transgene (Tg PECAM-GFP).12  Additional lines were WT, flt-1-/-
, and two sflt1 rescue lines, flt-1-/-;Tg PECAM-sflt-1#3312 and flt-1-/-;Tg PECAM-
sflt-1#26 that did not contain a GFP transgene.  All ES cell cultures were 
maintained and differentiated in vitro as described previously.46,47  Embryoid 
bodies (EBs) were plated onto slide flasks (Nunc, Rochester, NY) at day 3 of 
differentiation and cultured at 37oC in 5% CO2 until day 7-8, when time-lapse 
imaging was performed or they were fixed and stained. 
 
DNA constructs and electroporation 
The Sal I/Not I H2B-eGFP fragment was cut from pBOS-H2BGFP (BD 
Pharmingen, San Diego CA) and cloned into the PECAM promoter-enhancer 
vector12 for electroporation into WT ES cells (designated PECAM-H2B-GFP).  
The same fragment was also cloned into PECAM-Hygro12 for electroporation into 
flt-1-/- ES cells and designated PECAM-H2B-GFP-Hygro.  DNA was 
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electroporated into ES cells as described previously.12  Briefly, 20 µg of 
linearized PECAM-H2B-GFP or PECAM-H2B-GFP-Hygro DNAs were 
electroporated into 2 x 107 ES cells using a BioRad GenePulser II electroporator 
(250 V/300 µF; BioRad, Hercules, CA).  WT ES cell selection was in 200 µg/mL 
G418 (Gibco, Carlsbad, CA), and selection of flt-1-/- ES cells was in 200 µg/mL 
hygromycin B (Roche Diagnostics, Indianapolis, IN).   After 12 to 14 days, drug 
resistant ES colonies were picked, expanded, and analyzed by in vitro 
differentiation and fluorescence imaging.  We initially analyzed 5 WT transgenic 
lines (designated as WT;Tg PECAM-H2B-GFP) and 4 flt-1-/- transgenic lines 
(designated as flt-1-/-;Tg PECAM-H2B-GFP) that expressed the transgene in 
vessels and saw no differences except by genotype, so single WT and mutant 
lines were used for time-lapse imaging.  Generation of the sflt-1 rescue lines has 
been previously described.12 
 
Time-lapse imaging 
Slide flasks containing day-7 to -8 in vitro-differentiated ES cell cultures were 
sealed, then placed on a heated stage on a Nikon TE300 inverted microscope 
(Melville, NY) with a Perkin Elmer spinning disk confocal head (Shelton, CT).  
Confocal images were acquired at 1-minute intervals using Metamorph software 
(version 6.0; Universal Imaging Corp, Downing-town, PA) and a Hamamatsu Orca 
CCD camera (McHenry, IL) with 20X or 10X objectives as described.47  
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Antibody staining 
Following time-lapse imaging, ES cell cultures were rinsed with phosphate-
buffered saline (PBS) and fixed for 5 minutes in ice-cold methanol-acetone 
(50:50). Fixed cultures were reacted with rat anti-mouse PECAM at 1:1000 (MEC 
13.3; BD Pharmingen, San Diego, CA) and donkey anti-rat immunoglobulin G 
(IgG; H+L) conjugated to FITC or TRITC at 1:200 (Jackson Immunoresearch, 
West Grove, PA) as described previously.46,48  In some cases PECAM stained 
cultures were labeled with phosphohistone H3 as described,11 using rabbit anti-
phosphohistone at 1:500 (Upstate Biotechnology) and donkey anti-rabbit 
immunoglobulin G (IgG; H + L) conjugated to TRITC at 1:200 (Jackson 
Immunoresearch).  All cultures were viewed and photographed with an Olympus 
IX-50 inverted microscope (Melville, NY) outfitted with epifluorescence, or a Zeiss 
510 confocal microscope.    PECAM-stained images were aligned with the last 
frame of each movie using Photoshop version 7.0 (Adobe Systems, San Jose, 
CA).   
 
Retina dissection and staining  
Rat or mouse pups (P3-5) were weighed and anaesthetized by intraperitoneal 
injection of ketamine (20mg/kg) and xylazine (6 mg/kg) (rats) or by isofluorane 
inhalation (mice). Paraformaldehyde (PFA) was directly perfused (0.5 ml of 0.5% 
PFA) into the right ventricle, after which the pups were euthanized by intracardiac 
injection of Nembutol (80 mg/kg) (rats) or a thorectomy was performed (mice).  
Both eyes were enucleated and whole eyes were fixed in 2% PFA for 2 hours 
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before being washed in PBS.  The retinas were dissected using a modification of 
a described method.49,50  
The flat mounted retinas were incubated in ice cold ethanol for 30 minutes, 
then permeabilized with 1% Triton X-100 in PBS for 30 minutes.  The retinas 
were reacted with isolectin GS-I B4 conjugated to Alexa Fluor 488 at 1:100 
(Invitrogen, Carlsbad, CA) overnight at 4oC.  The samples were washed once 
with PBS, then blocked in 1% Triton X-100 and 5% goat serum in PBS for 1 hour.  
Antibodies and reaction conditions used were: rabbit polyclonal anti-phospho-
histone H3 at 1:500 (Upstate Biotechnology), overnight at 4oC, donkey anti-rabbit 
immunoglobulin G (IgG; H + L) conjugated to TRITC at 1:100 (Jackson 
Immunoresearch), 3 hours at 37oC.  All incubations were done in a humidity 
chamber and samples were washed 3 times with PBS after each antibody 
reaction.  Retinas were mounted in PBS:glycerol (2:1) and scanned on a Leica 
SP2 AOBS or a Zeiss 510 confocal microscope using a 40x 1.25 NA Apochromat 
objective.  
 
Quantitative image analysis 
Quantitative image analysis was performed using Metamorph software. Cell 
division planes were easily identified in H2B-GFP labeled vessels by bisection of 
the separating chromosomes during anaphase, and in anti-phospho-histone H3 
stained vessels by visualization of the metaphase or anaphase chromosomes.  
Lines were drawn along the division plane and along the long axis of the blood 
vessel for each mitotic division, and the angle between these two lines was 
calculated.  Angles of 0° are divisions whose cleavage pla nes are parallel to the 
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long axis of blood vessel, whereas angles of 90° are div isions whose cleavage 
planes are perpendicular to the long axis of blood vessel.  The angles were then 
grouped to every 10 degrees ranging from 0-90o.  Microsoft Office Word (2003) 
was used to generate line drawings of the angles.  Daughter cell separation was 
tracked for at least 60 minutes after division using time-lapse imaging and 
Metamorph software. 
 
C.  Results 
Endothelial cell divisions are oriented perpendicular to the vessel long axis 
in ES cell-derived vessels 
We reasoned that oriented endothelial cell divisions during angiogenic expansion 
of a vascular plexus might affect vessel morphogenesis by increasing either vessel 
length or vessel diameter (Fig. 3.1).  The cleavage plane was identified as a line 
between and parallel to the two groups of anaphase chromosomes (Fig. 3.2C).  
Thus a division oriented so that the plane of cytokinesis is perpendicular to the long 
axis of the vessel would effectively lengthen the vessel, while a division plane 
oriented parallel to the vessel long axis would increase the vessel diameter.  To 
determine if endothelial cell divisions are oriented in a flow-independent manner, we 
utilized a model of vascular development in which mouse ES cells undergo a 
programmed differentiation.  This process generates multiple embryonic cell types, 
including endothelial cells that form vessels and undergo sprouting 
angiogenesis.47,51  Although primitive hematopoietic cells also differentiate and the 
vessels form lumens in this 3-dimensional model of vessel development, there is no 
flow through the vessels.46  WT ES cells were generated with a stably integrated 
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transgene encoding histone H2B fused to GFP (H2B-GFP) linked to the PECAM 
enhancer/promoter (Tg PECAM-H2B-GFP).  Upon differentiation, these cultures 
expressed H2B-GFP in the developing primitive vessels, as shown by overlay with 
PECAM antibody stain (Fig. 3.2A).  The cultures were imaged for short periods (3-6 
hr) on day 7-8 of differentiation, when sprouting angiogenesis peaks, then fixed and 
stained for PECAM reactivity.  Endothelial divisions were scored during anaphase, 
and the angle of cleavage relative to the vessel long axis was determined (Fig. 
3.2B).  Analysis of the movies showed that the majority (56%) of the endothelial 
divisions were oriented within 10 degrees of perpendicular, and that 76% of divisions 
were within 20 degrees of perpendicular to the long axis of the vessel (Fig. 3.2B-D).  
This result shows that the endothelial cleavage plane is oriented relative to the long 
axis of the vessel, suggesting that oriented endothelial cell division participates in 
net lengthening of vessels in a developing vascular plexus.   
 
Daughter cells maintain their division orientation as they migrate and 
divisions orient relative to the nearest vessel axis 
To determine if the initial relationship of daughter cells following cleavage was 
maintained, the daughter nuclei produced by endothelial divisions were tracked 
for the duration of the movies (Fig. 3.3).  Divisions whose cleavage angle was 
70-90 degrees relative to the long axis of the vessel all had daughter nuclei that 
moved away from the cleavage plane along the long axis of the vessel (100%, 
61/61) (Fig. 3.3A).  Of the few divisions whose cleavage plane was 0-45 degrees 
relative to the vessel long axis, 70% (7/10) of daughter nuclei moved essentially 
perpendicular to the long axis of the vessel (Fig. 3.3B), while 30% (3/10) 
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reoriented and moved along the vessel long axis (Fig. 3.3C).  These results 
indicate that the orientation of endothelial cell divisions in vessels affects the 
subsequent spatial relationship of the daughter cells and thus can modulate 
vessel morphogenesis. 
We next asked whether the orientation of endothelial cell division is altered in 
and near forming sprouts.  To analyze sprout divisions, we utilized ES cell-derived 
vessels that contain a PECAM-eGFP transgene.12  This GFP reporter localized to 
the cytoplasm of endothelial cells, and it efficiently outlined the developing sprouts 
and endothelial cell divisions (Fig. 3.4).  We found that the orientation of endothelial 
division remained perpendicular to the vessel long axis when the division occurred in 
the parent vessel, whether prior to initiation of sprout formation (2/2, Fig. 3.4A) or 
subsequent to the initiation of sprout formation (6/6, Fig. 3.4B).  However, divisions 
within the sprout oriented perpendicular to the long axis of the sprout (5/5, Fig. 
3.4C).  Although the number of scored events was small, the uniform cleavage 
orientations suggest that endothelial divisions are normally oriented perpendicular to 
the current vessel axis, and not to a former or future vessel axis. 
 
 
Endothelial cell divisions are oriented perpendicular to the vessel long axis 
in retinal vessels in vivo  
To test the hypothesis that endothelial cell division orientation is also oriented in 
vivo, we examined post-natal rat retinas.  Vessel development occurs in a 
circumferential wave from the optic nerve in a single plane during the early post-
natal stages, and the leading edges of this vascular plexus were associated with 
high levels of division in cat retinas.49  Retinas were double stained with the Griffonia 
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B4 isolectin to visualize vessels, and anti-phospho-histone H3, which reacts with a 
histone epitope present on mitotic cells.52  This allows for visualization of condensed 
chromosomes during metaphase and anaphase, and by inference the division 
cleavage plane (Fig. 3.5).  Analysis of mitotic endothelial cells in which the cleavage 
plane could be scored (Fig. 3.5A) showed that 62% of the divisions were within 10 
degrees of perpendicular to the vessel long axis, and a total of 92% were within 20 
degrees of perpendicular (Fig. 3.5B-C).  These results indicate that the orientation of 
endothelial cell divisions perpendicular to the vessel long axis is recapitulated in 
vivo, in a developing vascular bed exposed to blood flow.   
 
VEGF signaling regulates endothelial cell division orientation in developing 
blood vessels 
Growth factor signaling is a key mediator of morphogenesis, and the HGF/scatter 
factor signaling pathway affects the division orientation of MDCK cells undergoing 
chain extension in 3-dimensional cultures.36  Thus we reasoned that VEGF signaling 
might be involved in the regulation of endothelial cell division orientation in 
developing vessels.  Proper regulation of signaling through VEGF-A is crucial to 
proper vessel morphogenesis, and excessive signaling through the VEGF-A 
receptor Flk-1 leads to vessel dysmorphogenesis.  We analyzed the plane of 
endothelial cell division in ES cell-derived vessels mutant for flt-1, which is a gain-of-
function for VEGF signaling through flk-1.53  These vessels also expressed PECAM-
H2B-GFP to allow for visualization of cleavage orientation (Fig. 3.6).  Although the 
vessel dysmorphogenesis associated with the mutation produces endothelial sheets 
with time, the edges of the sheets have distinguishable vessels whose long axis can 
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be scored (Fig. 3.6A).12  This analysis showed that the orientation of endothelial 
divisions in flt-1-/- vessels was randomized relative to WT vessels (Fig. 3.6B-C).  
Only 24% of divisions were within 10 degrees of perpendicular, as opposed to 56% 
of WT divisions.  Moreover, tracking of nuclei showed that 50% (8/16) of parallel 
divisions resulted in daughter nuclei that maintained the relationship they had at the 
time of division, indicating that these divisions can increase vessel diameter over 
length (data not shown).  These data show that perturbation of VEGF signaling leads 
to increased randomization of endothelial cell division orientation in developing 
vessels. 
To determine if the flt-1 mutation was responsible for the orientation phenotype, 
we asked whether the randomization of endothelial cell division orientation was 
rescued by a genetic rescue of the flt-1 mutation.  We previously showed that 
addition of a PECAM-sflt-1 transgene, that expresses the soluble isoform of flt-1 in 
developing vessels, rescued the reduction in branching morphogenesis seen in flt-1-
/-
 mutant vessels.12  We thus examined the orientation of endothelial cell division in 
two of the sflt-1 rescue lines, by double staining fixed cultures with anti-PECAM-1 to 
visualize vessels and anti-phospho-histone H3 to visualize condensed 
chromosomes for cleavage plane angle calculations (Fig. 3.7).  These data show 
that both flt-1-/-;Tg PECAM-sflt-1 lines rescued the randomized orientation of 
endothelial cell division seen in flt-1-/- mutant vessels (Fig. 3.7A-C).  In the flt-1-/-;Tg 
PECAM-sflt-1#33 and the flt-1-/-;Tg PECAM-sflt-1#26 vessels, 43% and 60% of 
endothelial cell divisions were within 10 degrees of perpendicular relative to the 
vessel long axis (Fig. 3.7B).  This compared to WT vessel values of 53% and flt-1-/- 
mutant vessel values of 17%.  Thus a genetic manipulation to rescue the 
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dysmorphogenesis of flt-1-/- mutant vessels rescues the orientation of endothelial cell 
division almost to WT levels. 
Next, we asked if mice expressing only VEGF120 had randomized division 
orientation.  Briefly, VEGF is expressed as three primary isoforms:  VEGF120, 
VEGF188 and VEGF165.  The isoforms differ in the ability to bind heparin sulfate 
proteoglycans in the extracellular space.17 VEGF188 and VEGF165 have heparin 
binding domains, and heparin binding “tethers” them near VEGF-expressing cells. 
VEGF120 does not bind heparin and is thought to diffuse far from VEGF-expressing 
cells, making it difficult for endothelial cells to sense a VEGF gradient.17  Mice 
expressing only one isoform have differing vascular phenotypes that are apparent in 
neonatal retinas.  Similar to flt-1-/- vessels, VEGF120/120 mice have thick vessels and 
decreased branching compared to wildtype vessels (Fig. 3.8A-B).17  We found that 
the difference between wildtype and VEGF120/120 retinal vessel division orientation 
was not significantly different, suggesting that the amount of VEGF signaling, as 
opposed to the VEGF pattern in the ECM, is important for regulation of endothelial 
division orientation (Fig. 3.8C). 
Interphase cell shape can regulate cell division orientation,31 and we wondered if 
perturbations in cell shape lead to randomized division orientation in flt-1-/- vessels. 
To assess cell shape, we determined the ratio of length/width of ES cell-derived 
endothelial cells and found that there is no detectable difference in cell shape 
between wildtype and flt-1-/- endothelial cells (data not shown), suggesting that the 
randomized division orientations observed in flt-1-/- vessels are not a result of 
abnormal cell shape.  
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Inhibition of JNK or Rho Kinase leads to randomized orientation of 
endothelial cell divisions 
Planar cell polarity (PCP) signaling regulates cell division orientation in a number 
of cell types,26 so we asked if inhibition of molecules that act downstream of PCP 
affected endothelial cell division orientation.  We found that inhibition of JNK or Rho 
Kinase resulted in randomized endothelial cell divisions in wildtype ES cell-derived 
vessels (Fig. 3.9), suggesting that JNK and Rho Kinase, perhaps acting downstream 
of PCP, are important for proper endothelial cell division orientation. 
 
D.  Discussion 
This study shows, for the first time, that endothelial cell division is normally 
oriented in developing vascular beds so that the cleavage plane is usually 
perpendicular to the long axis of the vessel.  This finding, along with evidence that 
daughter nuclei maintain the spatial relationships set up by the cleavage, indicates 
that oriented cell division is a novel mechanism contributing to vessel 
morphogenesis.  The oriented divisions can effectively extend vessel length.  Since 
developing vascular beds normally expand rapidly via the formation of many thin 
vessels, the bias of endothelial cell division orientation towards vessel lengthening is 
consistent with the overall morphogenetic program.   
Our finding that endothelial cell divisions orient perpendicular to the vessel long 
axis in both ES cell-derived vessels and in the post-natal retina indicates that 
regulated endothelial division orientation is a common attribute of developing 
vascular beds.  Moreover, the tight linkage between endothelial division orientation 
and the long axis of ES cell-derived vessels is striking, because there is no blood 
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flow in this model.  Numerous studies have linked aspects of endothelial cell polarity 
to the direction of shear stress produced by flow, including the orientation of the 
actin cytoskeleton, the microtubule network, and the position of the microtubule 
organizing center (MTOC).54-56  Recent work shows that endothelial cells can 
transduce mechanical shear stress to cell polarity pathways through a sensor that is 
comprised of PECAM-1, VE-cadherin, and VEGFR-2.57  Moreover, BrdU-labeled 
daughter cells are positioned to suggest division with cleavage perpendicular to the 
flow vector in rabbit carotid arteries, although cleavage orientation was not directly 
measured.58   
Our data show that endothelial cell division orientation is regulated in a flow-
independent manner, at least during the beginning stages of vessel extension.  
Developing vessels and sprouts do not form lumens capable of sustaining blood flow 
until later in the angiogenic process, and even then the shear stress values are 
significantly lower than those found in adult arteries,59 so a flow-independent 
mechanism to regulate endothelial division orientation might be predicted.  
Additionally, most vessels never experience the levels of shear stress found in major 
arteries, and the microcirculation has a low flow velocity.60,61  Thus, it seems 
plausible that a major component of endothelial cell division orientation operates 
independent of blood flow in vessels other than major arteries.  We found that retinal 
vessels, which have blood flow but not the shear stress of major vessels, had 92% 
of endothelial divisions within 20 degrees of perpendicular, and ES cell-derived 
vessels with no flow had 76% of endothelial divisions in the same category.  These 
data are consistent with a model in which flow-independent regulation of endothelial 
division orientation contributes substantially to vascular pattern formation.  
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Analysis of the divisions that occur in or near a sprout, the “sprout field”, shows 
that endothelial cells orient their cleavage plane perpendicular to the long axis of the 
structure in which they reside.  We did not find divisions within a parent vessel that 
oriented parallel to the long axis, as was seen in MDCK cells exposed to HGF and in 
mouse skin epithelium.29,36  Moreover, once a sprout formed we did not score 
divisions within the parent vessel that oriented with the sprout axis.  However, once 
an endothelial cell was in a sprout, its division oriented to the sprout axis.  Thus it 
appears that endothelial cells, unlike some other epithelial cells, do not use division 
orientation to initiate new morphogenetic structures, but rather to reinforce new 
sprouts once they have initiated. 
How is endothelial division orientation regulated?  Growth factor signaling is 
critical to this regulation in other models, and recently Wnt signaling was shown to 
be a positional cue for spindle orientation in early C. elegans embryos.62  Thus we 
asked whether VEGF signaling regulated endothelial division orientation in 
developing vessels, by examining vessels deleted for flt-1, which acts as a gain-of-
function mutation in VEGF signaling.9,11,53  Our analysis of flt-1-/- mutant vessels 
revealed that endothelial division orientation was randomized relative to the vessel 
long axis, consistent with a role for VEGF signaling in this process.  Moreover, 
introduction of a sflt-1 transgene that rescues branching morphogenesis in the flt-1 
mutant background also rescued the increased randomization of endothelial division 
orientation.  These data strongly support a role for VEGF signaling in the regulation 
of endothelial orientation in vessels.  Elevated VEGF signaling regulates the rate of 
endothelial cell division,11,13 and our data provide the first evidence showing that 
VEGF signaling also regulates the orientation of endothelial cell division.  
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Interestingly, we show that endothelial cell division orientation is not randomized in 
VEGF120/120 mice, suggesting that the amount of VEGF signaling, and not VEGF 
presentation, is important for regulation of division orientation.  It is well established 
that VEGF impacts vessel morphogenesis by regulating migration associated with 
sprout formation,4,12,17 and our data indicate that VEGF also affects the 
morphogenetic program via its ability to regulate endothelial cell division orientation.  
Our finding that endothelial division orientation is regulated indicates that 
integration between the endothelial cell division and morphogenesis programs 
occurs in developing vessels, and it suggests that morphogenetic signals regulate 
cell division.  While the VEGF signal itself is one point of integration, it is likely that 
morphogenesis and cell division are coordinated via cross-talk at multiple places in 
the downstream pathways.  In other organisms and tissues, division is oriented by 
the placement of the astral microtubules that emanate from the spindle poles on the 
cortex.  This placement is regulated by polarity determinants, and the polarity 
determinants in turn are spatially organized by the actin cytoskeleton.  Thus the 
VEGF signaling pathway is likely to intersect with one or more polarity pathways.  It 
is possible that VEGF signaling leads to differences in gene expression that affect 
polarity, but this is considered unlikely since most polarity information is imparted by 
spatial organization within the cell.  One likely intersection point is the actin 
cytoskeleton itself, since VEGF regulates actin dynamics.14,15  Thus the ability of 
VEGF to locally influence polymerization/depolymerization of the actin filaments 
could lead to spatial organization of polarity cues at the cortex.   The VEGF signaling 
pathway is also likely to intersect a planar cell polarity pathway, which orients cells in 
the plane of an epithelial sheet, since planar axis orientation must be regulated to 
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obtain the cleavage angles that we scored.  Moreover, one such pathway involving 
non-canonical Wnt signaling is implicated in the regulation of division orientation 
during zebrafish gastrulation.42  This intersection might occur at the level of the small 
GTPase Rho, since Rho is downstream of both pathways.63,64  Interestingly, we 
showed that treatment with JNK or Rho Kinase inhibitors randomizes endothelial cell 
division orientation, suggesting that VEGF may act through JNK and Rho to regulate 
endothelial cell division orientation. 
We have shown that endothelial cell division orientation is regulated early in 
vascular development in a flow-independent manner, and that this regulation can 
affect vessel morphogenesis.  This indicates that endothelial morphogenesis and 
cell division are integrated in developing vessels.  Moreover, disruption of the 
integration via perturbed VEGF signaling correlates with vessel dysmorphogenesis, 
suggesting that cross-talk between morphogenesis and division orientation is critical 
to proper vessel morphogenesis.  Thus endothelial cell division orientation 
represents another cellular process that is disrupted in dysmorphogenic vessels, and 
could therefore be a therapeutic target. 
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Figure 3.1.  Regulated endothelial cell division orientation may impact 
vessel morphogenesis – a model.  This model shows how endothelial cell 
divisions whose orientation is regulated relative to the long axis of the vessel 
could affect vessel shape.  Endothelial divisions oriented perpendicular to the 
vessel long axis (blue vessel on top) would effectively lengthen the vessel, 
whereas divisions oriented parallel to the vessel long axis (yellow vessel on 
bottom) would effectively increase the vessel diameter.  Microtubules and 
spindles are shown in red, and DNA/chromosomes are brown. 
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Figure 3.2.  Endothelial cell divisions are oriented perpendicular to the 
vessel long axis in ES cell-derived vessels.  Mouse ES cells (WT; Tg PECAM-
H2B-GFP) differentiated to day 7-8 were imaged for several hours prior to 
fixation and staining for PECAM-1.  A) A confocal image showing H2B-GFP 
signal in green (a), the same field with PECAM-1 stain in red after fixation (b), 
and the overlay of the two images (c), showing the H2B-GFP signal and PECAM-
1 stain in the same cells.  B) The top portion of the images in A, showing time 
lapse images from 0 minutes (a) to 292 minutes (f). Panel (d) was used to 
calculate the angle of division relative to the vessel axis, according to the drawn 
yellow lines.  The numbers in the lower right represent elapsed time in minutes.  
C) Calculation of division angles relative to the vessel long axis.  Top panel 
colorized as in Figure 1, except the chromosomes are blue.  90o division angle is 
perpendicular to the vessel long axis, and 0o division angle is parallel to the 
vessel long axis.  n = 125 divisions.  D) Representation of endothelial division 
angles, with the vessel long axis diagrammed by the long horizontal lines.  Each 
shorter line represents 3 angle measurements that were close or equivalent to 
each other.  See Fig2video1.mov in Supplemental Data for video of panel B. 
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Figure 3.3.  Daughter cells maintain their division orientation as they 
migrate after most divisions.  ES cell-derived vessels (WT; Tg PECAM H2B-
GFP) were imaged, and after divisions were scored (a panels) the two daughter 
nuclei (pink) were followed for 1-2 hours further.  The numbers in the lower right 
represent elapsed time in minutes.  In all cases b panels show the final image 
scored.  c panels diagram the movement of each daughter nucleus (shown in 
pink) after division: one daughter nucleus is tracked with a green line and the 
other with a pink line.  The vessel is shown by black lines, the vessel long axis is 
shown by the broken blue line, and the division angle is shown by the broken 
orange line.  A) A division perpendicular to the vessel long axis, where the 
daughter cells maintained the division orientation after 1 hour (n = 61/61).  B) A 
division parallel to the vessel long axis, where the daughter cells maintained the 
division orientation after 1 hour (n = 7/10).  C) A division parallel to the vessel 
long axis, where the daughter cells changed position relative to the division 
orientation after 102 minutes (n = 3/10). 
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Figure 3.4.  Endothelial cell divisions orient perpendicular to the nearest 
long axis.  ES cell-derived vessels (WT; Tg PECAM-eGFP) were imaged for 
various lengths of time, and divisions in or around sprouts scored for division 
orientation.  In all series, the yellow cell is the scored endothelial cell just prior to 
division, the pink cells are the daughter cells, and the numbers in the lower right 
represent elapsed time in minutes.  In all cases panel e diagrams the division 
that was scored, with the parent vessel long axis the broken blue line, the sprout 
long axis the dotted green line, and the division angle the broken orange line.  A) 
An endothelial division that occured prior to nearby sprout formation.  Although 
the sprout (arrows in panels c and d) migrated almost perpendicular to the vessel 
long axis, the division was oriented perpendicular to the parent vessel long axis 
(n = 2/2).  B) An endothelial division that occured in the sprout field, at the base 
of a formed sprout but in the parent vessel.  These divisions also oriented 
perpendicular to the parent vessel long axis (n = 6/6).  C) In contrast, an 
endothelial division that occured within a formed sprout oriented perpendicular to 
the sprout vessel long axis (n = 5/5).   
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Figure 3.5.  Endothelial cell divisions are oriented perpendicular to the 
vessel long axis in retinal vessels in vivo.  Rat retinas were harvested on 
days P3-5 and processed for staining as described with Griffonia B4 isolectin 
(green) to visualize vessels and phosphohistone H3 (red) to visualize DNA in 
mitotic cells.  A) Several examples of divisions in retinal vessels that were scored 
for division angle.  B) Calculation of division angles relative to vessel long axis.  
90o is perpendicular to the vessel long axis, and 0o is parallel to the vessel long 
axis.  n = 86 divisions.  C) Representation of endothelial division angles, with the 
vessel long axis diagrammed by the long horizontal lines.  Each shorter line 
represents 3 angle measurements that were close or equivalent to each other. 
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Figure 3.6.  Endothelial cell divisions are randomly oriented flt-1-/- ES cell-
derived vessels.  Mouse ES cells (flt-1-/-; Tg PECAM-H2B-GFP) differentiated to 
day 7-8 were imaged for several hours prior to fixation and staining for PECAM-
1.  A) Time lapse images of a representative movie from 0 minutes (a) to 240 
minutes (f), showing the H2B signal in vessels.  Panel (c) was used to calculate 
the angle of division relative to the vessel axis, according to the drawn yellow 
lines.  The numbers in the lower right represent elapsed time in minutes.  B) 
Calculation of division angles relative to the vessel long axis.  WT endothelial 
division angles are shown in blue, and flt-1-/- endothelial division angles are 
shown in purple.  90o is perpendicular to the vessel long axis, and 0o is parallel to 
the vessel long axis.  n = 125 divisions for WT vessels (same data as shown in 
Fig. 3.2) and n = 93 divisions for flt-1-/- vessels.  C) Representation of endothelial 
division angles, with the vessel long axis diagrammed by the long horizontal 
lines.  Each shorter line represents 3 angle measurements that were close or 
equivalent to each other. 
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Figure 3.7.  Randomized endothelial division orientation is rescued by a 
sflt-1 transgene that rescues flt-1-/- vessel dysmorphogenesis.  ES cell-
derived vessels were wild-type (WT), flt-1-/-, or flt-1-/- with a sflt-1 transgene (flt-1-/-
;Tg PECAM sflt-1#26 (sflt26) or flt-1-/-;Tg PECAM sflt-1#33 (sflt33)).  Cultures 
were differentiated to day 8, fixed, and stained for PECAM-1 (green) and 
phosphohistone H3 (red).  A) Representative vessels of the indicated genotypes, 
with white arrows pointing to endothelial divisions that were scored.  B) Graphic 
representation of division angles from the different genetic backgrounds.  90o is 
perpendicular to the vessel long axis, and 0o is parallel to the vessel long axis. 
WT is blue (n = 19), flt-1-/- is purple (n = 29), sflt26 is yellow (n = 25), and sflt33 is 
light green (n = 23).  C) Representation of endothelial division angles, with the 
vessel long axis diagrammed by the long horizontal lines.  Each shorter line 
represents a single angle measurement. 
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Figure 3.8.  Endothelial cell division orientation is not randomized in 
VEGF120/120 retinal vessels.  Postnatal day 5 VEGF120/120 and wildtype littermate 
mouse retinas were analyzed for endothelial cell division orientation.  (A-B) 
VEGF120/120 retinal vessels are overgrown compared to wildtype vessels.  
Vessels are labeled with Isolectin (green) and mitotic DNA is labeled with anti-
phospho-histone H3 (red).  Arrows in B point to thick vessels.  (C) Quantification 
of cell division orientation in VEGF120/120 vs. wildtype retinal endothelial cells. 
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Figure 3.9.  Inhibition of JNK or Rho Kinase results in randomization of 
endothelial division orientation.  Histone H2B::eGFP-expressing wildtype ES 
cells were differentiated and treated with JNK or Rho Kinase inhibitor for 4 hr. 
while movies were made.  Divisions were randomly oriented following (A) JNK 
inhibition (Untreated n=125 (same data as Fig. 3.2); JNK I n=78; p≤0.0001) or (B) 
Rho Kinase inhibition (Untreated n=4, Rho K I, n=18; p≤0.0001). Blue bars 
represent untreated conditions, red bars represent inhibitor treatment.  
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CHAPTER VI 
GENERAL DISCUSSION 
 
A.  VEGF and endothelial cell centrosome duplication 
In chapter two, I showed that elevated VEGF signaling through MEK/ERK and 
AKT to cyclin E/Cdk2 promotes centrosome over-duplication in endothelial cells.  
These findings are the first to illustrate a role for VEGF signaling in promoting 
centrosome duplication and, to our knowledge, the first to link growth factor 
signaling in general to centrosome duplication.  Because a number of debilitating 
diseases, including cancer, are dependent on or caused by elevated VEGF 
signaling, understanding how increased VEGF signaling affects blood vessel 
form and function is important for disease treatment and prevention. 
I showed that elevated VEGF signaling leads to centrosome over-duplication 
in flt-1-/- ES cell-derived vessels, flt-1-/- in vivo yolk sac vessels and cultured 
primary HUVEC.  I used HUVEC to dissect the signaling pathways linking VEGF 
and centrosome duplication.  High VEGF-treated HUVEC had increased cyclin E 
levels, Cdk2 activity and NPM phosphorylation compared to low VEGF-treated 
HUVEC, suggesting that VEGF activates cyclin E/Cdk2 to affect centrosome 
duplication.  My data showing that cyclin E knockdown in the presence of high 
VEGF signaling inhibits centrosome over-duplication confirm this model.  I also 
showed that high VEGF-treated HUVEC had increased ERK phosphorylation 
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compared to low VEGF-treated cells, and that inhibition of MEK signaling in the 
presence of high VEGF inhibited cyclin E accumulation and centrosome over-
duplication, suggesting that VEGF signals through MEK/ERK to affect cyclin E 
levels and centrosome duplication.  Additionally, VEGF is known to promote 
endothelial cell survival via signaling through AKT, and I showed that elevated 
cyclin E accumulation and centrosome over-duplication were blocked in HUVEC 
treated with high VEGF+AKT inhibitor.  Treatment with AKT inhibitor did not block 
high VEGF-induced ERK phosphorylation, suggesting that AKT regulates cyclin 
E accumulation and centrosome duplication independent of MEK/ERK signaling.  
Prior to my work, it was clear that cyclin E/Cdk2 activity is important for 
promoting centrosome duplication; and, my data are the first to link VEGF 
signaling and cyclin E/Cdk2-regulated centrosome duplication.  Further 
dissection of the pathways that act downstream of VEGF to regulated cyclin 
E/Cdk2 activity will be an important step toward understanding centrosome 
duplication in endothelial cells and other cell types.  For example, the signaling 
pathway from ERK to cyclin E that regulates DNA replication is relatively well 
characterized, but whether or not cyclin E is also regulated by molecules specific 
to centrosome duplication signaling is unknown.  It is possible that there exist 
centrosome duplication-specific molecules that act downstream of ERK to 
promote cyclin E transcription or cyclin E/Cdk2 activity and centrosome 
duplication. 
I showed that high VEGF-treated HUVEC with excess centrosomes formed 
aberrant spindles during mitosis, and that flt-1-/- ES cell-derived endothelial cells 
displayed increased aneuploidy compared to wildtype cells.  Interestingly, tumor 
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endothelial cells, which experience very high VEGF signaling, have excess 
centrosomes and display aneuploidy.1,2  Aneuploidy leads to abnormal cellular 
behaviors in other cell types and aneuploid endothelial cells likely behave 
abnormally as well.  For example, endothelial cells that contain excess copy 
numbers of cell cycle-promoting genes may display increased cell proliferation 
and vascular overgrowth, similar to flt-1-/- vessels.  Over time, aneuploidy that is 
advantageous to tumor growth and survival can lead to clonal tumor cell 
populations,3 in which most of the tumor cells contain the same aneuploidy 
patterns.  The cells are clonal because they out-compete (proliferate faster, 
survive longer) other tumor cells.  Advantageous aneuploidy in tumor endothelial 
cells could also lead to clonal tumor endothelial cell populations.  For example, 
clonal endothelial cell populations that have a proliferative advantage may form 
blood vessels faster than normal endothelial cells, thus allowing the tumors to 
grow and metastasize faster.  I did not observe clonal aneuploidy in 8 day 
differentiated flt-1-/- ES cell-derived endothelial cells (data not shown); however, it 
is possible that aneuploid endothelial populations in tumor blood vessels, which 
form over months or years, have sufficient time to become clonal.  In the future, it 
will be interesting to determine if tumor endothelial cell populations are clonal, 
and if so, whether aneuploidy patterns are consistent from one tumor to the next. 
Such studies would shed light on which genes are important for endothelial cell 
function in tumors, and they would potentially provide additional targets for anti-
tumor blood vessel therapies. 
Not only did flt-1-/- endothelial cells display increased aneuploidy, they also 
displayed chromosomal aberrations that were not present in wildtype cells, 
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including chromosome breaks and triradials, which are thought to result from 
asymmetrical chromatid exchange.  It is unclear why these gross chromosomal 
abnormalities are present in flt-1-/- endothelial cells.  It is possible that excess 
VEGF signaling in flt-1-/- endothelial cells promotes cyclin E accumulation (as it 
does in HUVEC) and that elevated cyclin E accumulation bypasses the DNA 
damage checkpoint during S phase, resulting in chromosomal aberrations; or, 
that VEGF affects DNA repair pathways independent of cyclin E.  Another 
possibility is that anaphase spindle abnormalities, such as centrosome clustering 
and multipolar spindle formation, induce chromosomal abnormalities due to 
unequal pulling forces on the chromosomes.  Whatever the case, in the future, it 
will be interesting to determine how flt-1-/- endothelial cells obtain these 
chromosomal aberrations and whether or not the same abnormalities are 
observed in tumor vessels and other endothelial cells that experience high VEGF 
signaling.   
We predicted that wildtype ES cell-derived endothelial cells would not display 
aneuploidy, but we were surprised to find that 13/25 (52%) wildtype endothelial 
cells (vs. 21/25, 84% in flt-1-/- cells) were aneuploid.  It is possible that wildtype 
ES cell-derived vessels display high aneuploidy because the blood vessels 
develop in an in vitro system, and the pressures to maintain proper endothelial 
cell chromosome number (and ultimately cellular function) may not be as strong 
as those in vivo.  In the future, it will be important to assess aneuploidy in 
wildtype vs. flt-1-/- vessels in vivo, such as those in developing yolk sac. 
I also showed that endothelial cells with excess centrosomes are enriched at 
the leading edge of in vitro scratch wounds, suggesting that endothelial cells 
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containing excess centrosomes may have a migratory advantage compared to 
cells with normal centrosome numbers.  How excess centrosomes affect 
migration is unclear, but two likely scenarios emerge.  First, increased migration 
of endothelial cells containing excess centrosomes may be linked to centrosome-
mediated microtubule dynamics.  Centrosomes act as the microtubule nucleating 
centers in the cell.  It is possible that having excess centrosomes allows for 
increased microtubule nucleation and increased migration.  Second, it is possible 
that endothelial cells containing excess centrosomes are largely aneuploid, and 
that endothelial cells containing excess copy numbers of genes that promote 
migration may have a migratory advantage.  Understanding if and how 
centrosome number affects cell migration will be critical, both in terms of 
understanding how endothelial cells with excess centrosomes migrate, but also 
in terms of understanding the process of migration as a whole. 
I showed that elevated FGF signaling also promotes centrosome over-
duplication in endothelial cells.  This result is very intriguing because it suggests 
that angiogenic factors other than VEGF can regulate centrosome duplication. 
Tumor vessels that are exposed to VEGF inhibitors regress for a short time, but 
eventually re-grow and retain morphological and functional abnormalities.4-6  My 
results suggest that in tumors, centrosome over-duplication might occur even in 
the absence of VEGF signaling due to elevated levels of other angiogenic factors 
such as FGF.  Furthermore, while VEGF signaling is specific to endothelial cells, 
FGF activates signaling pathways in a number of different cell types.7  It is 
possible that FGF and other molecules that activate MEK/ERK and/or AKT 
signaling promote centrosome duplication in other cell types.  In any case, my 
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finding that VEGF and FGF lead to excess centrosome numbers in endothelial 
cells is important because it provides novel mechanisms to explain how vascular 
abnormalities occur in the presence of high growth factor signaling. 
In the big picture, regulation of endothelial cell centrosome number may be 
important for the development of anti-tumor vessel therapies.  As previously 
mentioned, anti-tumor vessel therapies only cause vessel regression for a short 
time period, after which endothelial cells (likely those with proliferative/survival 
advantages) re-populate the tumor.  Recently, a number of groups proposed that 
tumor vessels must first be normalized before they will robustly respond to anti-
vessel therapies.4-6  One way to normalize endothelial cells is to target 
endothelial cells that that are abnormal, such as those containing excess 
centrosomes.  Ganem, et al (2009) and Silkworth, et al (2009) showed that cells 
that contain excess centrosomes die if they divide with multipolar spindles, as 
opposed to clustered centrosome spindles.8-9  Thus, if endothelial cells 
containing excess centrosomes are forced to divide with multipolar spindles, it 
might be possible to kill off the cells that contain excess centrosomes.  
Interestingly, Ganem, et al (2009) showed that knockdown of histone 
deacetylase (HDAC) gene expression forced cells containing excess 
centrosomes to divide with multipolar spindles, resulting in cell death.  It is 
possible that inhibition of HDAC in tumor endothelial cells will cause endothelial 
cells containing excess centrosomes to die following multipolar cell divisions, 
ultimately yielding normalized tumor vessels.  
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B.  VEGF and endothelial cell division orientation 
In chapter three, Dr. Gefei Zeng and I characterized a role for VEGF signaling 
in regulating endothelial cell division orientation.  We showed that endothelial cell 
divisions are oriented to increase the length of developing blood vessels in ES 
cell-derived vessels and in vivo in retinal vessels, and that division orientation is 
blood flow-independent.  We also showed that endothelial cell division orientation 
was randomized in vessels exposed to elevated VEGF signaling via the flt-1-/- 
mutation.  
Mis-oriented cell divisions are associated with abnormal morphology in other 
tissue types.  For example, oriented divisions are required for zebrafish body 
elongation, and randomized divisions result in stunted embryos.10  We showed 
that endothelial cells divide to increase the long axis of blood vessels undergoing 
active angiogenesis in ES cell-derived vessels and neonatal retinal vessels.  We 
also showed that elevated VEGF signaling randomized division orientation in flt-
1-/- vessels.  Here, randomized division orientation was associated with 
dysmorphogenic vascular overgrowth, and it is possible that mis-oriented 
divisions contribute to the dysmorphogenic phenotype.  In the future, it will be 
important to determine if developing blood vessels exposed to high VEGF 
signaling in vivo, such as flt-1-/- yolk sac vessels or tumor vessels, also have mis-
oriented cell divisions. 
How VEGF regulates cell division orientation remains unclear.  I assessed 
division orientation in VEGF120/120 neonatal mouse retinal vessels because the 
vessels are thick compared to wildtype vessels.  Endothelial cell division 
orientation was not random in VEGF120/120 retinal vessels.  Because VEGF120 is 
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expressed form the endogenous VEGF locus in VEGF120/120 mice, it is assumed 
that VEGF presentation (localization in the ECM), but not VEGF concentration is 
disrupted.  This suggests that the amount of VEGF signaling, and not VEGF 
presentation, is important for the regulation of endothelial cell division orientation.  
It is possible that VEGF feeds into a planar cell polarity (PCP) signaling pathway 
that is important for regulating division orientation in other cell types.11  
Consistent with this hypothesis, inhibition of molecules that act downstream of 
PCP signaling, JNK and Rho Kinase, leads to randomization of endothelial cell 
division orientation.  Alternatively, VEGF signaling may affect endothelial cell 
division orientation independent of PCP signaling.  In any case, understanding 
how VEGF regulates endothelial cell division orientation will be an exciting and 
important contribution to the field of vascular biology.  
Does centrosome number affect endothelial cell division orientation?  I 
showed that elevated VEGF signaling leads to both centrosome over-duplication 
and mis-oriented cell divisions in endothelial cells, and that centrosome number 
can affect mitotic spindle formation.  Thus, in high VEGF conditions, it is tempting 
to speculate that mis-oriented endothelial cell divisions result from excess 
centrosome-induced clustered or multipolar spindles.  In this model, a normal 
endothelial cell with two centrosomes forms a bipolar spindle to increase the 
length of an existing vessel, while an endothelial cell with three centrosomes may 
form a tripolar spindle, in which two spindles cluster in a random orientation prior 
to anaphase.  Using a DNA label (like we did in Chapter 2) to assess division 
orientation, the spindle would appear to be a mis-oriented bipolar spindle.  
However, as opposed to VEGF playing a direct role in regulating endothelial cell 
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division orientation, the mis-orientation would be an indirect consequence of 
VEGF-induced centrosome over-duplication.  We showed that 76% of flt-1-/- 
endothelial cell divisions were mis-oriented, while 11% had excess centrosomes.  
If centrosome over-duplication were the sole cause of mis-oriented divisions in 
flt-1-/- vessels, then I would expect there to be an equal or higher percentage of 
cells with excess centrosomes compared to mis-oriented divisions.  Thus, it is 
unlikely that all of the mis-oriented cell divisions observed in flt-1-/- endothelial 
cells are a result of centrosome over-duplication; however, it is possible that 
centrosome over-duplication partially contributes to mis-oriented divisions. 
In conclusion, I described two novel roles for VEGF signaling in regulating 
endothelial cell function and vascular morphology.  I showed that elevated VEGF 
signaling promotes centrosome over-duplication in endothelial cells, and 
endothelial cell centrosome over-duplication is associated with aneuploidy and 
cellular dysfunction.  I also showed that elevated VEGF signaling randomizes 
endothelial cell division orientation, which likely contributes to vascular 
overgrowth in vessels exposed to high VEGF signaling. These novel 
contributions to the field of vascular biology are important for understanding how 
VEGF signaling affects both normal and pathological blood vessel formation. 
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